Trim7 inhibitors and uses thereof

Abstract

The present disclosure relates to compositions and methods, including Trim / inhibitors that find use in the treatment of disease, such as therapies for cancer, including cancers that are resistant to anti-checkpoint agents, infectious diseases and inflammatory diseases.

Description

[0001] TRIM7 INHIBITORS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and benefit of U.S. Provisional Patent Application No.63 / 520,551, filed on August 18, 2023, U.S. Provisional Patent Application No.63 / 561,076, filed March 4, 2024, and U.S. Provisional Patent Application No.63 / 631,138, filed April 8, 2024, the contents of all of which are hereby incorporated by reference in their entireties. FIELD OF THE DISCLOSURE The present disclosure relates to, inter alia, compositions and methods, including compounds including Trim7 inhibitors that find use in the treatment of disease, such as therapies for cancer, including cancers that are resistant to anti- checkpoint agents, infectious diseases and inflammatory diseases. SEQUENCE LISTING The instant application contains a sequence listing, which has been submitted in XML format via EFS-Web. The contents of the XML copy named “SHK-085PC_116981-5085-WO_Sequence_Listing,” which was created on August 15, 2024 and is 4,096 bytes in size, the contents of which are incorporated herein by reference in their entirety. BACKGROUND Drug resistance remains one of the biggest challenges in cancer therapy. Drug resistance is found across all types of cancer and all modes of treatment, including molecularly targeted therapy, immunotherapy, and chemotherapy. In some patients, initiation of efficacious therapy is delayed by the inability to predict responses. Moreover, it is also common that a patient with advanced cancer receives a drug that helps shrink their tumors, but then the cancer develops resistance to the drug. Unfortunately, few effective therapeutic options are available for some patients having cancers that are resistant to the anti-checkpoint therapies. Therefore, methods for developing new therapies for patients suffering from drug resistant cancer are required for improving outcomes in cancer patients. SUMMARY Accordingly, the present disclosure provides, in part, compositions and methods for treating cancer, including, without limitations, cancers that are resistant to anti-checkpoint agents. Also provided are methods for treating infectious diseases and infectious diseases and inflammatory diseases. Also provided are methods for selecting patients for cancer treatment, and methods for cancer treatment, based on, for instance, based on gene expression profiles of Trim7, which is dysregulated in anti-checkpoint resistant cancers. In one embodiment, the present disclosure provides a compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein in formula (I): L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1is an integer from 0 to 5; t is 1 or 2; with the proviso that the compound of formula (I) is not a compound of any one of formulas 1001, 1003, 1004, and 1006-1009: In some embodiments, the compound is a compound of formula (I) wherein R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, optionally substituted with halo, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -C(O)Ra, -C(O)N(Ra)2, -N(Ra)2, -N(Ra)C(O)Ra, and -S(O)tRa. In some embodiments, the compound is a compound of formula (I) wherein L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10 cycloalkenyl-, -C1-10alkynyl-, -O-C1-10alkynyl-, -C1-10aryl-, -O-C1-10-, -aryl-,-cycloalkyl-, -heterocyclyl-, -O-, -S-, -S-S-, - S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, -N(Rb)C(O)-, -OC(O)N(Rb)-, - N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, -N(Rb)S(O)w-, -S(O)wN(Rb)-, - S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O-)3, wherein w is 1 or 2, and Rbis independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, optionally L is a bond and / or - C(O)- and / or -C(H)(CH2)pC(O)NH2, and / or , wherein p is an integer from 1-5, optionally p is 2; optionally L is , wherein the alkyl is substituted or unsubstituted, In some embodiments, the compound of formula (I) is a compound of formula (10): wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2 is an integer from 0 to 5; and t is 1 or 2. In some embodiments, the compound of formula (I) is a compound of formula (20) or (21): wherein in formula (20) and (21): n3 is an integer from 0 to 5. In some embodiments, the compound of formula (I) is a compound of formula (30) or (31): wherein in formula (30) and (31): p is an integer from 0 to 5. In some embodiments, the compound of formula (I) is a compound of formula (32): wherein in formula (32): q is an integer from 1 to 3. In some embodiments, the compound of formula (I) is a compound of formula (40): wherein in formula (40): n4is an integer from 0 to 5. In some embodiments, the compound of formula (I) is a compound of formula (50): wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5 is an integer from 0 to 5; and t is 1 or 2. In some embodiments, the compound of formula (I) is a compound of formula (60): wherein in formula (60): n6is an integer from 0 to 5. In some embodiments, the compound of formula (I) is a compound of formula (70): wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, the compound of (70) is a compound of formula (700) or (701): In some embodiments, the compound of formula (I) is a compound of formula (80) or formula (81): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5; wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, the compound of formula (80) is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803): In some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R5band / or R5cis each independently selected from unsubstituted or substituted alkynyl, optionally substituted alkynyl, substituted aryl, substituted heteroaryl, halo, optionally Br, -N(Ra)2, optionally -NH2 , and -N(Ra)C(O)Ra, optionally optionally w5b herein R is selected from , , , , , , , , optionally wherein R5cis selected from , , , , , , , , and . In some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R11aand R11bare each unsubstituted alkyl, or R11aand R11bare each independently , or R11ais selected from H and unsubstituted alkyl and R11bis or R11ais H and R11bis unsubstituted alkyl, wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3-C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7is 1 or 2. In some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R11aand R11bare each independently selected from , , , and , optionally wherein R11aand R11bare each independently selected from . In some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R11a is selected from H and -CH3 and R11bis selected from , optionally wherein R11ais selected from H and -CH3 and R11bis selected from some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R11ais selected from H and -CH3 and R11bis selected from some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein R11ais H and R11bis -CH3 or wherein R11aand R11bare each -CH3. In some embodiments, the compound of formula (I) is a compound of any one of formula (80), (81), or (800)-(803) wherein n8is 1. In some embodiments, the compound of formula (I) is a compound of formula (82): formula (82) wherein in formula (82): R11a, R11b,R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, the compound of formula (82) is a compound of formula (804) or (805): formula (804) formula (805). In some embodiments, the compound of formula (I) is a compound of formula (90): formula (90) wherein in formula (90): n is an integer from 1 to 5. In some embodiments, the compound of formula (90) is a compound of formula (900), formula (901), or formula (902): In some embodiments, the compound of formula (I) is a compound of any one of formula (90), (900), (901), or (902), wherein R12is H or -CH3. In some embodiments, the compound of formula (I) is a compound of any one of formula (90), (900), (901), or (902), wherein R11ais H or substituted alkyl, optionally , optionally . In some embodiments, the compound of formula (I) is a compound of any one of formula (90), (900), (901), or (902), wherein R10is -C(O)Ra, optionally wherein Rais selected from unsubstituted alkenyl, substituted alkyl, substituted aryl, and substituted heterocyclyl, or R10is -S(O)tRa, optionally wherein t is 2 and Rais substituted aryl. In some embodiments, the compound of formula (I) is a compound of any one of formula (90), (900), (901), or (902), wherein R10is selected from: In some embodiments, the compound of formula (I) is a compound of any one of formula 1002, 1005, 1010-1098, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient: wherein in formula (I): A is selected from L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1 is an integer from 0 to 5; and t is 1 or 2. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) wherein R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, optionally substituted with halo, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -N(Ra)2, -C(O)Ra, -C(O)N(Ra)2, -N(Ra)C(O)Ra, and - S(O)tRa. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) wherein L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, - C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10cycloalkenyl-, -C1-10alkynyl-, -O-C1-10alkynyl-, -C1-10aryl- , -O-C1-10-, -aryl-,-cycloalkyl-, -heterocyclyl-, -O-, -S-, -S-S-, -S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, - OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, -N(Rb)C(O)-, -OC(O)N(Rb)-, -N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S- , -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, -N(Rb)S(O)w-, -S(O)wN(Rb)-, -S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O- , (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O-)3, wherein w is 1 or 2, and Rbis independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, optionally L is a bond and / or -C(O)- and / or -C(H)(CH2)pC(O)NH2, and / or , wherein p is an integer from 1-5, optionally p is 2, optionally L is l is substituted or unsubstituted, , . In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (10): wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2is an integer from 0 to 5; and t is 1 or 2. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (20) or (21): wherein in formula (20) and (21): n3 is an integer from 0 to 5. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (30) or (31): wherein in formula (30) and (31): p is an integer from 0 to 5. thereof. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (32): wherein in formula (32): q is an integer from 1 to 3. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (40): wherein in formula (40): n4 is an integer from 0 to 5. In some embodiments, the pharmaceutical composition comprises a of formula (I) which is a compound of formula (50): wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5 is an integer from 0 to 5; and t is 1 or 2. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (60): wherein in formula (60): n6 is an integer from 0 to 5. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (70): wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, pharmaceutical composition comprises a compound of formula (70) which is a compound of formula (700) or (701): In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (80) or formula (81): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5; wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, the pharmaceutical composition comprises a compound of formula (80) which is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803): In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (82): wherein in formula (82): R11a, R11b,R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In some embodiments, the pharmaceutical composition comprises a compound of formula (82) which is a compound of formula (804) or (805): In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of formula (90): wherein in formula (90): n is an integer from 1 to 5. In some embodiments, the pharmaceutical composition comprises a compound of formula (90) which is a compound of formula (900), formula (901), or formula (902): In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of any one of formula 1001-1098, or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises a compound of formula (I) which is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof. In yet another aspect, the present disclosure provides a method for treating a cancer, an infectious disease, an inflammatory disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition comprising a compound of any one of formula (I), (10), (20), (21), (30)-(32), (40), (50), (60), (70), (80), (81), (82), (90), (700), (701), (800)-(805), (900), (901), or (902). In some embodiments, the cancer is selected from a basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs’ syndrome. In some embodiments, the cancer is a hematologic cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt’s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non- Hodgkin’s lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and pre-leukemia, or a combination thereof. In some embodiments, the cancer is resistant to an anti-checkpoint agent. In some embodiments, the anti-checkpoint agent is an antibody, optionally selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and anti-CTLA antibody. In some embodiments, the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). In some embodiments, the infectious disease is a viral infection. In some embodiments, the viral infection is caused by a virus selected from papilloma virus, herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis virus, Zika virus, Yellow Fever Virus, West Nile virus, Dengue virus, Japanese Encephalitis Virus, St. Louis Encephalitis Virus, Hepatitis C Virus, poliovirus, rhinovirus, enterovirus, coxsackievirus, influenza virus, lentivirus, respiratory syncytial virus, a human parainfluenza virus, rubulavirus (e.g., mumps virus), measles virus, human metapneumovirus, hantavirus, rotavirus, norovirus, and SARS virus (e.g., SARS-CoV-2). In some embodiments, the inflammatory disease is an autoimmune disease or condition, selected from multiple sclerosis, diabetes mellitus, lupus, celiac disease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, scleroderms, Goodpasture's syndrome, Wegener's granulomatosis, autoimmune epilepsy, Rasmussen's encephalitis, Primary biliary sclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addison's disease, Hashimoto's thyroiditis, Fibromyalgia, Menier's syndrome; transplantation rejection (e.g., prevention of allograft rejection) pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, and other autoimmune disease. In yet another aspect, the present disclosure provides a method for treating an anti-checkpoint agent-resistant cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition comprising a compound of any one of formula (I), (10), (20), (21), (30)-(32), (40), (50), (60), (70), (80), (81), (82), (90), (700), (701), (800)-(805), (900), (901), or (902). In some embodiments, the anti-checkpoint agent is an antibody, optionally selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and anti-CTLA antibody. In some embodiments, the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). In yet another aspect, the present disclosure provides a method of determining a cancer treatment for a patient, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and selecting the cancer therapy comprising the pharmaceutical composition comprising a compound of any one of formula (I), (10), (20), (21), (30)-(32), (40), (50), (60), (70), (80), (81), (82), (90), (700), (701), (800)-(805), (900), (901), or (902) if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In yet another aspect, the present disclosure provides a method for selecting a patient for a cancer treatment, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition comprising a compound of any one of formula (I), (10), (20), (21), (30)-(32), (40), (50), (60), (70), (80), (81), (82), (90), (700), (701), (800)- (805), (900), (901), or (902) if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In yet another aspect, the present disclosure provides a method of treating cancer, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) administering the cancer therapy comprising the pharmaceutical composition comprising a compound of any one of formula (I), (10), (20), (21), (30)-(32), (40), (50), (60), (70), (80), (81), (82), (90), (700), (701), (800)- (805), (900), (901), or (902) if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally administering a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In some embodiments, the biological sample used in any one of the above methods is a fresh tissue sample, frozen tumor tissue specimen, cultured cells, circulating tumor cells, or a formalin-fixed paraffin-embedded tumor tissue specimen. In some embodiments, the biological sample used in any one of the above methods is a biopsy sample, optionally wherein the biopsy sample is selected from endoscopic biopsy, bone marrow biopsy, endoscopic biopsy (e.g., cystoscopy, bronchoscopy and colonoscopy), needle biopsy (e.g., fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, X-ray-assisted biopsy, computerized tomography (CT)-assisted biopsy, magnetic resonance imaging (MRI)-assisted biopsy and ultrasound-assisted biopsy), skin biopsy (e.g., shave biopsy, punch biopsy, and incisional biopsy) and surgical biopsy. In some embodiments, the biological sample used in any one of the above methods comprises a body fluid selected from blood, plasma, serum, lacrimal fluid, tears, bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage such as a ductal lavage or broncheoalveolar lavage, aspirate, scraping, bone marrow specimen, tissue biopsy specimen, surgical specimen, feces, other body fluids, secretions, and / or excretions, and / or cells therefrom. In some embodiments, the biological sample used in any one of the above methods comprises at least one tumor cell. In some embodiments, the evaluating used in any one of the above methods is performed by DNA sequencing, RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof. In some embodiments, the evaluating used in any one of the above methods is performed by contacting the sample with an agent that specifically binds to Trim7. In one embodiment, the agent that specifically binds to one or proteins comprises an antibody, antibody-like molecule or binding a fragment thereof. In some embodiments, the evaluating used in any one of the above methods is performed by contacting the sample with an agent that specifically binds to one or more of nucleic acids of Trim7. In some embodiments, the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe. Any aspect or embodiment disclosed herein can be combined with any other aspect or embodiment as disclosed herein. BRIEF DESCRIPTION OF THE FIGURES The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. FIG.1A and FIG.1B show the binding of recombinant human (rh) Trim7 to RACO1 and MSK1 in vitro as measured using a Meso Scale Discovery (MSD) platform-based assay. FIG.1A shows the binding to human Trim7 by RACO1 in comparison with CD47, which was used as a negative control. FIG.1B shows the binding to human Trim7 by MSK1 in comparison with CD47, which was used as a negative control. FIG.2 shows the binding of recombinant human (rh) Trim7 to enterovirus 712B or enterovirus 712BC proteins in vitro as measured using a Meso Scale Discovery (MSD) platform-based assay. Recombinant human RACO1 and MSK1 proteins were used as positive controls and recombinant human CD47 protein was used as a negative control. FIG.3A and FIG.3B show that the enterovirus 712BC protein inhibits the binding of recombinant human (rh) Trim7 to MSK1 (FIG.3A) and RACO1 (FIG.3B) in vitro as measured using a Meso Scale Discovery (MSD) platform-based assay. FIG.4 shows the crystal structure of Trim7 bound to the CVB_2C (319-329) peptide (SVGTTLEALFQ), which is the C- terminal fragment of the Coxsackievirus B3 (CVB3)_2C protein. Left top panel shows a schematic representation of the CVB3 C2 protein, showing the location of the CVB_2C (319-329) peptide. Left bottom panel shows crystal structure of CVB_2C protein, showing the CVB_2C (319-329) peptide, and a crystal structure of the Trim7 protein complexed with the CVB_2C (319-329) peptide. Right panel shows the interactions of the CVB_2C (319-329) peptide with various amino acids of Trim7 protein. FIG.5 shows a schematic representation of the molecular simulation-based method used for identification of Trim7 inhibitors, including compound of formula 1. FIG.6 shows various docked compounds. The underlined compounds have a docking score better than -7, indicative of likely affinity constant of <100nM. FIG.7 shows representative compounds along with their docking scores. FIG.8A and FIG.8B show docking of compound 1009. FIG.8A shows compound 1001 in the context of space filling model of Trim7 in the background. FIG.8B shows the binding of compound 1001 to Trim7. FIG.9A, FIG.9B, and FIG.9C show the elucidation of the Trim7 crystal structure that partially informed the Trim7 SMIs of the present disclosure. FIG.10 provides data confirming TRIM7 interactions with RACO-1, STING, MAVS, and CVB3_2C (WT but not mutant). FIG.11 is a scheme showing an exemplary workflow for screening and prioritizing candidates. FIG.12A and FIG.12B provides data from cell-based activity assays demonstrating that TRIM7 expression in cells results in target degradation / stabilization. FIG.12A demonstrates that the over expression of TRIM7 (+T7) in 293T cell lines expressing CVB3, MAVS, or STING results in their degradation. FIG.12B is an assay showing that compound 1028 blocks TRIM7 stabilization of RACO1, resulting in its degradation. DETAILED DESCRIPTION Disclosed herein are Trim7 inhibitors that are useful, inter alia, for the treatment of disease, such as therapies for cancer, including cancers that are resistant to anti-checkpoint agents, infectious diseases and autoimmunity. Drug resistance, either existing before treatment (intrinsic or primary resistance) or developed after therapy (acquired resistance), is responsible for many relapses of cancer, one of the major causes of death. Therefore, better understanding the mechanisms of drug resistance is required to provide guidance to future cancer treatment. It was reported that anti-PD-1 resistant tumors exhibit a paradoxical dysregulation of some IFNγ-induced genes, with Trim7 being a driver gene involved in the paradoxical dysregulation, and anti-PD-1 resistance. See International Application No. PCT / US2021 / 061834, which is incorporated herein by reference in its entirety. Accordingly, disclosed herein are Trim7 inhibitors that are useful, inter alia, for the treatment of cancers that are resistant to anti-checkpoint agents. Since Trim7 is involved in diverse processes such as tumor growth, innate immunity and pathogenesis of viral infection, the Trim7 inhibitors disclosed herein find use in the treatment of cancer, infectious diseases and autoimmunity. Trim7 Tripartite motif (TRIM) proteins are a group of E3 ubiquitin ligases that are involved in different cellular functions. Many TRIM proteins are induced by type I and type II interferons (IFN-I or IFN-II) or pathogen stimulations, in different cell types including human and mouse primary immune cells. Rajsbaum et al., Type I interferon-dependent and - independent expression of tripartite motif proteins in immune cells. Eur J Immunol.2008;38(3):619-630; Carthagena et al., Human TRIM gene expression in response to interferons. PLoS One 2009;4(3):e4894. The consensus N-terminal region of TRIM proteins contains a RING finger domain followed by one or two B-box domains and a coiled-coil domain (CC). Each TRIM protein has a specific C-terminal domain, which confers substrate specificity via protein-protein interactions. The C-terminal domains include PRY and / or SPRY domains (B30.2). Tripartite Motif Containing 7 (Trim7) is known to have roles in tumor cell proliferation, glycogen metabolism, innate immunity (e.g., via IFN induction), virus pathogenesis. Giraldo et al., Envelope protein ubiquitination drives entry and pathogenesis of Zika virus. Nature 2020.10.1038 / s41586-020-2457-8; Montori-Grau et al., GNIP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle. Metabolism.2018;83:177–187; Lu et al., E3 ubiquitin ligase tripartite motif 7 positively regulates the TLR4-mediated immune response via its E3 ligase domain in macrophages. Mol Immunol.2019;109:126-133. Without wishing to be bound by theory, it is believed that MSK1 directly phosphorylates Trim7. Trim7 has also been shown to act as an E3 ligase mediating K63-linked polyubiquitination of the AP-1 coactivator RACO-1, leading to RACO-1 protein stabilization. Chakraborty et al., The E3 ubiquitin ligase Trim7 mediates c-Jun / AP-1 activation by Ras signaling. Nat Commun. 2015;6:6782. Trim7 has also been described to negatively regulate responses to DNA viruses by targeting STING for degradation. Yang et al., RNF90 negatively regulates cellular antiviral responses by targeting MITA for degradation. PLoS Pathog.2020;16(3):e1008387. Trim7 was identified as one of the genes that was identified as dysregulated in model of acquired resistance for an anti-PD-1 antibody. See International Application No. PCT / US2021 / 061834, which is incorporated herein by reference in its entirety. Trim7 Inhibitors As used herein, the term “alkyl” denotes branched or unbranched hydrocarbon chains, having about 1 to 10 carbons, such as, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, 2-methylpentyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethyl pentyl, octyl, 2,2,4-trimethylpentyl, and the like. “Substituted alkyl” includes an alkyl group optionally substituted with one or more functional groups which are attached commonly to such chains, such as, hydroxy, halogen, mercapto or thio, cyano, alkylthio, carboxy, nitro, alkoxy, or optionally substituted, alkyl, amino, alkenyl, carboxamido, carbalkoxy, alkynyl, heterocyclyl, aryl, heteroaryl, and the like to form alkyl groups such as trifluoromethyl, 3-hydroxyhexyl, 2-carboxypropyl, 2-fluoroethyl, carboxymethyl, cyanobutyl, phenethyl, benzyl, and the like. The term “halogen” or “halo” as used herein alone or as part of another group refers to chloro, bromo, fluoro, or iodo. The term “alkoxy” refers to alkyl-O-, in which alkyl is as defined above. The term “alkylthio” refers to alkyl-S-, in which alkyl is as defined above. The term “alkylamino” refers to –NR’R”, in which R’ and R” each may independently represent H, alkyl, or aryl, all as defined herein. The term “alkylcarbonyl” refers to –C(=O)-alkyl, in which alkyl is as defined above. The term “carboxy” refers to the moiety –C(=O)OH. The term “carbalkoxy” refers to the moiety –C(=O)-O-alkyl, in which alkyl is as defined above. The term “carboxamido” refers to the moiety –C(=O)-NR’R”, in which R’ and R”, each may independently represent H, alkyl, or aryl, all as defined herein. The term “alkylsulfonyl” refers to the moiety –S(=O)2-alkyl, in which alkyl is as defined above. The term “arylsulfonyl” refers to the moiety –S(=O)2-aryl, in which aryl is as defined herein. For example, arylsulfonyl may be –S(=O)2-phenyl. The term “arylsulfonyloxy” refers to the moiety –OS(=O)2-alkyl, wherein alkyl is as defined above. The term “amino(monoalkylamino-, dialkylamino-)sulfinyl” refers to the moiety –S(=O)NR’R”, in which R’ and R” each may independently represent H, alkyl, or aryl, all as defined herein. The term “amino(monoalkylamino-, dialkylamino-)sulfonyl” refers to the moiety –S(=O)2NR’R”, in which R’ and R” each may independently represent H, alkyl, or aryl, all as defined herein. The term “alkylsulfonylamino” refers to the moiety –NHS(=O)2-alkyl, in which alkyl is as previously defined. The term “hydroxysulfonyloxy” refers to the moiety –OS(=O)2OH. The term “alkoxysulfonyloxy” refers to the moiety –OS(=O)2O-alkyl, in which alkyl is as defined above. The term “alkylsulfonyloxy” refers to the moiety –OS(=O)2-alkyl, in which alkyl is as previously defined. The term “hydroxysulfonyl” refers to the moiety –S(=O)2OH. The term “alkoxysulfonyl” refers to the moiety –S(=O)2O-alkyl, wherein alkyl is as previously defined. The term “alkylsulfonylalkyl” refers to the moiety –alkyl-S(=O)2-alkyl, wherein each alkyl may be as previously defined. The term “amino(monoalkylamino-, dialkylamino-)sulfonylakyl” refers to the moiety –alkyl-S(=O)2-NR’R”, wherein alkyl is as previously defined, and R’ and R” each may independently represent H, alkyl, or aryl, all as defined herein. The term “amino(monoalkylamino-, dialkylamino-)sulfinylalkyl” refer to the moieties –alkyl-S(=O)-NR’R”, wherein alkyl is as previously defined, and R’ and R” each may independently represent H, alkyl, or aryl, all as defined herein. Unless otherwise indicated, the term “cycloalkyl” as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or more double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, and cyclohexenyl. “Substituted cycloalkyl” includes a cycloalkyl group optionally substituted with 1 or more substituents such as halogen, alkyl, substituted alkyl, alkoxy, hydroxy, aryl, substituted aryl, aryloxy, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and / or alkylthio and / or any of the substituents included in the definition of “substituted alkyl.” Unless otherwise indicated, the term “alkenyl” as used herein by itself or as part of another group refers to straight or branched chain of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 2 to 8 carbons in the normal chain, which include one or more double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4- pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3- undecenyl, 4-dodecenyl, 4,8, 12-tetradecatrienyl, and the like. “Substituted alkenyl” includes an alkenyl group optionally substituted with one or more substituents, such as the substituents included above in the definition of “substituted alkyl” and “substituted cycloalkyl.” Unless otherwise indicated, the term “alkynyl” as used herein by itself or as part of another group refers to straight or branched chain of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one or more triple bonds in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3- pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4- dodecynyl and the like. “Substituted alkynyl” includes an alkynyl group optionally substituted with one or more substituents, such as the substituents included above in the definition of “substituted alkyl” and “substituted cycloalkyl.” Unless otherwise indicated, the term “aryl” or “Ar” as employed herein alone or as part of another group refers to monocyclic, bicyclic, and / or polycyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring, such as aryl, cycloalkyl, heteroaryl, or cycloheteroalkyl rings or substituted forms thereof. “Substituted aryl” includes an aryl group optionally substituted with one or more functional groups, such as halo, alkyl, haloalkyl (e.g., trifluoromethyl), alkoxy, haloalkoxy (e.g., difluoromethoxy), alkenyl, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, alkylcarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are optionally substituted alkyl, aryl or any of the other substituents recited herein), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylaminocarbonyl, arylaminocarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, or arylsulfonaminocarbonyl and / or any of the alkyl substituents recited herein. The term “arylalkyl” refers to –alkyl-aryl, in which alkyl and aryl are as defined above. Unless otherwise indicated, the term “heteroaryl” as used herein alone or as part of another group refers to a 5- to 7- membered aromatic ring which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur and such rings fused to an aryl, cycloalkyl, heteroaryl or heterocycloalkyl ring (e.g. benzothiophene, indole, quinoline, thiazole, isooxazole, benzothiazole, benzimidizole, isoquinoline, pyridine, pyrimidine, benzopyrone, oxazole, thiazole, pyrazine), and includes possible N-oxides. “Substituted heteroaryl” includes a heteroaryl group optionally substituted with 1 to 4 substituents, such as the substituents included above in the definition of “substituted alkyl” and “substituted cycloalkyl.” Substituted heteroaryl also includes fused heteroaryl groups which include, for example, quinoline, isoquinoline, indole, isoindole, carbazole, acridine, benzopyrene, benzopyrone, benzimidazole, benzofuran, isobenzofuran, phenanthroline, purine, and the like. Moreover, the terms “heterocyclo,” “heterocycle,” “heterocyclyl,” or “heterocyclic ring,” as used herein, refer to an unsubstituted or substituted stable 5- to 7-membered monocyclic ring system which may be saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from N, O or S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic groups include, but are not limited to, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, pyrrolyl, pyrrolidinyl, benzothiophene, chromone, benzopyrene, benzopyrone, furanyl, thienyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isooxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, thiadiazolyl, tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide, thiamorpholinylsulfone, and oxadiazolyl. The term “heteroarylalkyl” refers to –alkyl-heteroaryl, in which alkyl and heteroaryl are as defined above. As used herein, the terms “optionally substituted” or “substituted” may indicate that a chemical moiety referred to, for example, alkyl, aryl, and heteroaryl, may be unsubstituted or substituted with one or more groups including, without limitation, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heterocycle, substituted heterocycle, heteroaryl, substituted heteroaryl, hydroxyl, amino, substituted amino, alkoxy, substituted alkoxy, halogen, carboxy, nitro, carbalkoxy, substituted carbalkoxy, carboxamido, substituted carboxamido, alkylamino, substituted alkyl amino, monoalkylaminosulfinyl, substituted, monoalkylaminosulfinyl, dialkylaminosulfinyl, substituted dialkylaminosulfinyl, monoalkylaminosulfonyl, substituted monoalkylaminosulfonyl, dialkylaminosulfonyl, substituted dialkylaminosulfonyl, alkylsulfonylamino, substituted alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, substituted alkoxysulfonyloxy, alkylsulfonyloxy, substituted alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, substituted alkoxysulfonyl, alkylsulfonylalkyl, substituted alkylsulfonylalkyl, monoalkylaminosulfonylalkyl, substituted monoalkylaminosulfonylalkyl, dialkylaminosulfonylalkyl, substituted dialkylaminosulfonylalkyl, monoalkylaminosulfinylalkyl, substituted monoalkylaminosulfinylalkyl, dialkylaminosulfinylalkyl, substituted dialkylaminosulfinylalkyl, and the like. The chemical moieties of a formula (I), formula (10), formula (20), formula (21), formula (30), formula (31), formula (32), formula (40), formula (50), formula (60), formula (70), formula (80), formula (81), formula (82), formula (90), formula (700), formula (701), formula (800), formula (801), formula (802), formula (803), formula (804), formula (805), formula (900), formula (901), formula (902), or formula 1001-1098, or a pharmaceutically acceptable salt thereof, above, that may be optionally substituted include alkyl, alkenyl, alkynyl, cycloalkyl, arylalkyl, aryl, heterocycle, and heteroaryl, as described herein. For example, optionally substituted alkyl may include both propyl and 2-chloro-propyl. Additionally, “optionally substituted” is also inclusive of embodiments where the named substituent or substituents have multiple substituents rather than simply a single substituent. For example, optionally substituted aryl may include both phenyl and 3-ethyl-5-methyl-6-bromo-phenyl. The compounds of the disclosure may be administered as salts, which are also within the scope of this disclosure. Pharmaceutically acceptable (i.e., non-toxic, physiologically compatible) salts are preferred. If the compounds of the disclosure have, for example, at least one basic center, they can form acid addition salts. These are formed, for example, with strong inorganic acids, such as mineral acids, for example sulfuric acid, phosphoric acid or a hydrohalic acid, with strong organic carboxylic acids, such as alkane carboxylic acids of 1 to 4 carbon atoms which are unsubstituted or substituted, for example, by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, for example ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, (for example aspartic or glutamic acid or lysine or arginine), or benzoic acid, or with organic sulfonic acids, such as (C1-C4) alkyl or arylsulfonic acids which are unsubstituted or substituted, for example by halogen, for example methyl- or paratoluene-sulfonic acid. Corresponding acid addition salts can also be formed having plural basic centers, if desired. In embodiments, the pharmaceutically acceptable salt is selected from valproic acid, maleic acid, tartaric acid, oxalic acid, pamoic acid, phosphonic acid, benzoic acid, citric acid, salicylic acid, succinic acid, methanesulfonic acid, malic acid, and p-toluenesulfonic acid. In embodiments, the pharmaceutically acceptable salt is selected from valproic acid, maleic acid, tartaric acid, oxalic acid, and pamoic acid. The compounds of the disclosure having at least one acid group (e.g., carboxylic acid) can also form salts with suitable bases. Representative examples of such salts include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono, di or trihydroxy lower alkylamine, for example ethyl, tert-butyl, diethyl, diisopropyl, triethyl, tributyl or dimethyl-propylamine, or a mono, di or trihydroxy lower alkylamine, for example mono, di or triethanolamine. Corresponding internal salts may also be formed. For example, certain salts of the compounds described herein which contain a basic group include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate. Moreover, certain salts of the compounds described herein which contain an acid group include sodium, potassium and magnesium salts and pharmaceutically acceptable organic amines. All stereoisomers of the compounds of the disclosure, either in a mixture or in pure or substantially pure form, are considered to be within the scope of this disclosure. The compounds of the disclosure may have asymmetric centers at any of the carbon atoms including any one of the substituents. Consequently, compounds of the disclosure may exist in enantiomeric or diastereomeric forms or in mixtures thereof. Furthermore, where a stereocenter existing in a compound of the disclosure is represented as a racemate, it is understood that the stereocenter may encompass the racemic mixture of R and S isomers, the S isomers, and the R isomers. The processes for preparation of such compounds can utilize racemates, enantiomers, or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods including, chromatographic, chiral HPLC, fractional crystallization, or distillation. Some compounds of the present disclosure have groups including alkenyls, iminyls, and the like, which may exist as entgegen (E) or zusammen (Z) conformations, in which case all geometric forms thereof, both E and Z, cis and trans, and mixtures thereof, are within the scope of the present disclosure. Accordingly, when such geometric isomeric products are prepared, they can be separated by conventional methods for example, chromatographic, HPLC, distillation or crystallization. In one aspect, the present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof: wherein in formula (I): L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1is an integer from 0 to 5; and t is 1 or 2; with the proviso that the compound of formula (I) is not a compound of any one of formulas 1001, 1003, 1004, and 1006-1009: In embodiments, R1a, R1b, R2 , R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -C(O)Ra, -N(Ra)2, -N(Ra)C(O)Ra, and -S(O)tRa. In embodiments, the aryl is aryl substituted with halo. In embodiments, L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10 cycloalkenyl-, -C1-10 alkynyl-, -O-C1-10 alkynyl-, -C1-10 aryl-, -O-C1-10-, -aryl-,-cycloalkyl-, - heterocyclyl-, -O-, -S-, -S-S-, -S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, - N(Rb)C(O)-, -OC(O)N(Rb)-, -N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, - N(Rb)S(O)w-, -S(O)wN(Rb)-, -S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O- )3, wherein w is 1 or 2, and Rbis independently hydrogen, unsubstituted or substituted alkyl, or unsubstituted or substituted aryl, wherein p is an integer from 1-5. In embodiments, p is 2. In embodiments, L is a bond. In embodiments, L is -C(O)-. In embodiments, L is -C(H)(CH2)pC(O)NH2. In embodiments, L is . In embodiments, L is , wherein the alkyl is substituted or unsubstituted. In embodiments, L is , . I ts, the compound of formula (I) is a compound of formula (10): formula (10) wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2 is an integer from 0 to 5; and t is 1 or 2. In embodiments, n2is 2. In embodiments, R1ais C1-6alkyl. In embodiments, R1ais -CH3. In embodiments, R2is H. In embodiments, R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen and halo. In embodiments, halo is F or Cl. In embodiments, R9a, R9b, R9c, R9d, and R9eare each hydrogen. In embodiments, R9a, R9d, and R9eare each hydrogen. In embodiments, R9bis Cl. In embodiments, R9cis F. In embodiments, embodiments, the compound of formula (I) is a compound of formula (20) or (21): formula (20) formula (21) wherein in formula (20) and (21): n3is an integer from 0 to 5. In embodiments, n3is 2. In embodiments, R4ais H. In embodiments, R4bis H. In embodiments, R3is C1-6alkyl. In embodiments, R3is -CH3. In embodiments, the compound of formula (I) is a compound of formula (20), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (21), or a pharmaceutically acceptable salt thereof. In embodiments, embodiments, the compound of formula (I) is a compound of formula (30) or (31):

[0002] formula (30) formula (31) wherein in formula (30) and (31): p is an integer from 0 to 5. In embodiments, p is 2. In embodiments, R5a, R5b, R5c, R5d, and R5eare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is -CH3.In embodiments, halo is F or Cl. In embodiments, R5a, R5c, R5d, and R5eare each hydrogen. In embodiments, R5dis -CH3. In embodiments, the compound of formula (I) is a compound of formula (30), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (31), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (32): formula (32). wherein in formula (32): q is an integer from 1 to 3. In embodiments, q is 1. In embodiments, R5a, R5b, R5c, and R5dare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is - CH3. In embodiments, halo is F or Cl. In embodiments, R5a, R5b, R5c, and R5dare each hydrogen. In embodiments, the compound of formula (I) is a compound of formula (70): formula (70) wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, R5aand R5dare each hydrogen. In embodiments, the compound of formula (70) is a compound of formula (700) or (701): formula (700) formula (701). In embodiments, the compound of formula (70) is a compound of formula (700), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (70) is a compound of formula (701), or a pharmaceutically acceptable salt thereof. In embodiments, R5bis selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and - N(Ra)C(O)Ra. In embodiments, R5cis selected from selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and -N(Ra)C(O)Ra. In embodiments, the halo is Br. In embodiments, the substituted aryl is . I . In embodiments, -N(Ra)2, is -NH2. In embodiments, the aa alkynyl is optionally unsubstituted alkynyl. In embodiments, -N(R)C(O)R is , , In embodiments, R11aand R11bare each independently , wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3- C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7is 1 or 2. In embodiments, R11aand R11bare each independently selected from d Iai , In embodiments, R11ais H and R11bis unsubstituted alkyl. In embodiments, R11ais H and R11bis -CH3. In embodiments, R11aand R11bare each independently unsubstituted alkyl. In embodiments, R11aand R11bare each -CH3. In embodiments, the compound of formula (I) is a compound of formula (80): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5. In embodiments, R5aand R5dare each hydrogen. In embodiments, n8is 1. In embodiments, the compound of formula (I) is a compound of formula (81): formula (81) wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, R5aand R5dare each hydrogen. In embodiments, the compound of formula (80) is a compound of formula (800) formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803): formula (802) formula (803). In embodiments, the compound of formula (80) is a compound of formula (800), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (80) is a compound of formula (801), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (81) is a compound of formula (802), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (81) is a compound of formula (803), or a pharmaceutically acceptable salt thereof. In embodiments, R5bis selected from unsubstituted or substituted alkynyl, substituted heteroaryl, substituted aryl, halo, -N(Ra)2, and -N(Ra)C(O)Ra. In embodiments, R5bis selected from substituted aryl and -N(Ra)C(O)Ra. In embodiments, R5cis selected from selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and - N(Ra)C(O)Ra. In embodiments, R5cis substituted aryl. In embodiments, the halo is Br. In embodiments, the substituted aryl is . In embodiments, the substituted aryl is . In embodiments, the substituted aryl is . In embodiments, the substituted aryl embodiments, -N(Ra)2, is -NH2. In embodiments, the alkynyl is optionally unsubstituted alkynyl. In embodiments, -N(Ra)C(O)Rais . In , , , , , embodiments, n8is 1. In embodiments, Alk is C1-C5alkyl. In embodiments, Alk is C1-C3alkyl. In embodiments, Alk is methyl. In embodiments, Alk is C1-C5alkyl substituted with aryl. In embodiments, Alk is . In embodiments, R11aand R11bare each independently unsubstituted alkyl. In embodiments, R11aand R11bare each independently C1-C5alkyl. In embodiments, R11aand R11bare each independently C1-C3alkyl. In embodiments, R11aand R11bare each independently methyl. In embodiments, R11aand R11bare each independently , wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3-C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5 alkoxy, and n7 is an integer from 1 to 3, optionally n7 is 1 or 2. In embodiments, R11aand R11bare , y s

[0003] , , In embodiments, R11ais selected from H and unsubstituted alkyl, optionally methyl, and R11bis . In embodiments, R11ais selected from H and -CH3 and R11bis selected from , a , In embodiments, R11ais H and R11bis unsubstituted alkyl. In embodiments, R11ais H and R11bis -CH3. In embodiments, R11aand R11bare each independently unsubstituted alkyl. In embodiments, R11aand R11bare each -CH3. In embodiments, the compound of formula (I) is a compound of formula (82): formula (82) wherein in formula (82): R11a, R11b, R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, the compound of formula (82) is a compound of formula (804) or (805): In embodiments, the compound of formula (82) is a compound of formula (804), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (82) is a compound of formula (805), or a pharmaceutically acceptable salt thereof. In embodiments, R5band / or R5cis each independently -ORa, wherein Rais unsubstituted alkyl, optionally wherein - ORais -OCH3. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently cyclohexyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently alkyl substituted with cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently -CH2- substituted with cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently I embodiments, the compound of formula (I) is a compound of formula (90): formula (90) wherein in formula (90): n is an integer from 1 to 5. In embodiments, the compound of formula (90) is a compound of formula (900), formula (901), or formula (902): formula (900) formula (901) formula (902). In embodiments, the compound of formula (90) is a compound of formula (900), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (90) is a compound of formula (901), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (90) is a compound of formula (902), or a pharmaceutically acceptable salt thereof. In embodiments, R12is H. In embodiments, R12is -CH3. In embodiments, R11ais H. In embodiments, R11ais substituted alkyl. In embodiments, R11ais alkyl substituted with aryl. In embodiments, . In embodiments, embodiments, R10is -C(O)Ra. In embodiments, R10is -C(O)Rawherein Rais unsubstituted alkenyl. In embodiments, R10is . In embodiments, R10is -C(O)Rawherein Rais substituted alkyl. In embodiments, aryl. In embodiments, embodiments, R10is -C(O)Rawherein Rais substituted heterocyclyl. In embodiments, embodiments, R10is -S(O)tRa. In embodiments, R10is -S(O)tRawherein t is 2. In embodiments, R10is - S(O)tRawherein t is 2 and Rais substituted aryl. In embodiments, R10is In embodiments, the compound of formula (I) is a compound of any one of formula 1002, 1005, 1010-1098, or a pharmaceutically acceptable salt thereof:

[0004] In embodiments, the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof:

[0005] In embodiments, embodiments, the compound of formula (I) is a compound of formula (40): wherein in formula (40): n4is an integer from 0 to 5. In embodiments, n4is 0. In embodiments, R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and unsubstituted or substituted alkyl. In embodiments, the alkyl is alkyl substituted with amido, and amido. In embodiments, R6a, R6b, R6c, R6d, and R6eare each independently selected f , I formula (50) wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5 is an integer from 0 to 5; and t is 1 or 2. In embodiments, n5 is 3. In embodiments, R7a, R7b, R7c, R7d, R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is -CH3. In embodiments, halo is F or Cl. In embodiments, R7a, R7b, R7c, and R7dare each hydrogen. In embodiments, R10a, R10b, R10d, and R10eare each hydrogen. In embodiments, R10cis F. In embodiments, A is . In embodiments, the compound of formula (I) is a compound of formula (60): formula (60) wherein in formula (60): n6is an integer from 0 to 5. In embodiments, n6is 1. In embodiments, R9is H. In embodiments, the compound of the disclosure (e.g. a compound of any one of formula (I), formula (10), formula (20), formula (21), formula (30), formula (31), formula (32), formula (40), formula (50), formula (60), formula (70), formula (80), formula (81), formula (82), formula (90), formula (700), formula (701), formula (800), formula (801), formula (802), formula (803), formula (804), formula (805), formula (900), formula (901), formula (902), or formula 1001- 1098) is a non-covalent inhibitor of Trim7. In a non-limiting example, a non-covalent inhibitor does not form a covalent bond with the Trim7 gene product (e.g. a covalent bond with an amino acid of the Trim7 gene product). In embodiments, the compound of the disclosure (e.g. a compound of any one of formula (I), formula (10), formula (20), formula (21), formula (30), formula (31), formula (32), formula (40), formula (50), formula (60), formula (70), formula (80), formula (81), formula (82), formula (90), formula (700), formula (701), formula (800), formula (801), formula (802), formula (803), formula (804), formula (805), formula (900), formula (901), formula (902), or formula 1001-1098) is a covalent inhibitor of Trim7. In a non-limiting example, a covalent inhibitor forms and / or is capable of forming a covalent bond with the Trim7 gene product (e.g. a covalent bond with an amino acid of the Trim7 gene product). Non-limiting examples of covalent Trim7 inhibitors include compounds comprising one or more moiety capable of forming a covalent bond with the Trim7 gene product, including but not limited to alkenes, such as alkenes that are Michael acceptors, as would be understood by one of ordinary skill in the art. Non-limiting examples of alkenes include -C(O)-CH=CH2moieties. Pharmaceutical compositions Aspects of the present disclosure include a pharmaceutical composition comprising the Trim7 inhibitors any of the herein disclosed aspects or embodiments. In one aspect, the present disclosure relates to a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient: wherein in formula (I): , L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1 is an integer from 0 to 5; and t is 1 or 2. In embodiments, R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -C(O)Ra, -C(O)N(Ra)2, -N(Ra)2, -N(Ra)C(O)Ra, and - S(O)tRa. In embodiments, the aryl is aryl substituted with halo. In embodiments, L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, - C1-10cycloalkenyl-, -O-C1-10cycloalkenyl-, -C1-10alkynyl-, -O-C1-10alkynyl-, -C1-10aryl-, -O-C1-10-, -aryl-,-cycloalkyl-, - heterocyclyl-, -O-, -S-, -S-S-, -S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, - N(Rb)C(O)-, -OC(O)N(Rb)-, -N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, - N(Rb)S(O)w-, -S(O)wN(Rb)-, -S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O- )3, wherein w is 1 or 2, and Rbis independently hydrogen, unsubstituted or substituted alkyl, or unsubstituted or substituted aryl, wherein p is an integer from 1-5. In embodiments, p is 2. In embodiments, L is a bond. In embodiments, L is C(O)-. In embodiments, L is -C(H)(CH2)pC(O)NH2. In embodiments, L is . In embodiments, L is , wherein the alkyl is substituted or unsubstituted. In embodiments, L is , . In embodiments, embodiments, the compound of formula (I) is a compound of formula (10): formula (10) wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2 is an integer from 0 to 5; and t is 1 or 2. In embodiments, n2is 2. In embodiments, R1ais C1-6alkyl. In embodiments, R1ais -CH3. In embodiments, R2is H. In embodiments, R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen and halo. In embodiments, halo is F or Cl. In embodiments, R9a, R9b, R9c, R9d, and R9eare each hydrogen. In embodiments, R9a, R9d, and R9eare each hydrogen. In embodiments, R9bis Cl. In embodiments, R9cis F. In embodiments, embodiments, the compound of formula (I) is a compound of formula (20) or (21): formula (20) formula (21) wherein in formula (20) and (21): n3 is an integer from 0 to 5. In embodiments, n3 is 2. In embodiments, R4ais H. In embodiments, R4bis H. In embodiments, R3is C1-6alkyl. In embodiments, R3is -CH3. In embodiments, the compound of formula (I) is a compound of formula (20), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (21), or a pharmaceutically acceptable salt thereof. In embodiments, embodiments, the compound of formula (I) is a compound of formula (30) or (31):

[0006] formula (30) formula (31) wherein in formula (30) and (31): p is an integer from 0 to 5. In embodiments, p is 2. In embodiments, R5a, R5b, R5c, R5d, and R5eare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is -CH3.In embodiments, halo is F or Cl. In embodiments, R5a, R5c, R5d, and R5eare each hydrogen. In embodiments, R5dis -CH3. In embodiments, the compound of formula (I) is a compound of formula (30), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (31), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (32): formula (32). wherein in formula (32): q is an integer from 1 to 3. In embodiments, q is 1. In embodiments, R5a, R5b, R5c, and R5dare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is - CH3. In embodiments, halo is F or Cl. In embodiments, R5a, R5b, R5c, and R5dare each hydrogen. In embodiments, the compound of formula (I) is a compound of formula (70): formula (70) wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, R5aand R5dare each hydrogen. In embodiments, the compound of formula (70) is a compound of formula (700) or (701): formula (700) formula (701). In embodiments, the compound of formula (70) is a compound of formula (700), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (70) is a compound of formula (701), or a pharmaceutically acceptable salt thereof. In embodiments, R5bis selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and - N(Ra)C(O)Ra. In embodiments, R5cis selected from selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and -N(Ra)C(O)Ra. In embodiments, the halo is Br. In embodiments, -N(Ra)2, is -NH2. In embodiments, the alkynyl is optionally unsubstituted alkynyl. In embodiments, -N(Ra)C(O)Rais . In embodiments, - . In embodiments, -N(Ra)C(O)Rai In embodiments, R11aand R11bare each independently , wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3- C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7is 1 or 2. In embodiments, R11aand R11bare each independently selected from In embodiments, R11ais selected from H and -CH3 and R11bis selected from , . In embodiments, R11ais H and R11bis unsubstituted alkyl. In one embodiment, R11ais H and R11bis -CH3. In embodiments, R11aand R11bare each independently unsubstituted alkyl. In one embodiment, R11aand R11bare each - CH3. In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein R5bor R5cis - N(Ra)C(O)Ra. In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein 5b 5c R or R is . In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein R11ais , n7 is 1, and Y is optionally substituted phenyl and R11bis selected from H, alkyl, tetrahydropyran, and wherein n7is 1, and Y is optionally substituted phenyl. In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein both R11aand R11bare independently , n7is 1, and Y is optionally substituted phenyl and at least one optionally substituted phenyl is substituted with one or more halogen, alkyl, or CX3, wherein X is a halogen selected from F, Cl, Br, and I. In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein both R11aand R11bare independently , n7is 1, and Y is optionally substituted phenyl and both optionally substituted phenyl are substituted with one or more alkoxy, optionally -OCH3. In embodiments, the compound of formula (I) is a compound of formula (700) or formula (701) wherein: R5bor R5cis -N(Ra)C(O)Ra, optionally , R11ai wherein n7is 1, and Y is optionally substituted phenyl and R11bis selected from H, alkyl, tetrahydropyran, and wherein n7is 1, and Y is optionally substituted phenyl, or R11aand R11bare each independently wherein n7 is 1, and Y is optionally substituted phenyl wherein at least one optionally substituted phenyl is substituted with one or more halogen, alkyl, or CX3, wherein X is a halogen selected from F, Cl, Br, and I, or R11aand R11bare each independently wherein n7 is 1, and Y is optionally substituted phenyl wherein each optionally substituted phenyl is independently substituted with one or more alkoxy, optionally -OCH3. In embodiments, the compound of formula (700) or formula (701) is a compound of any one of formulas 1020-1027, 1029, 1030, 1078-1081, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of formula (80): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5. In embodiments, R5aand R5dare each hydrogen. In embodiments, n8is 1. In embodiments, the compound of formula (I) is a compound of formula (81): wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, R5aand R5dare each hydrogen. In embodiments, the compound of formula (80) is a compound of formula (800), formula (801), formula (802), or formula (803): formula (802) formula (803). In embodiments, the compound of formula (80) is a compound of formula (800), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (80) is a compound of formula (801), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (81) is a compound of formula (802), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (81) is a compound of formula (803), or a pharmaceutically acceptable salt thereof. In embodiments, R5bis selected from unsubstituted or substituted alkynyl, substituted heteroaryl, substituted aryl, halo, -N(Ra)2, and -N(Ra)C(O)Ra. In embodiments, R5bis selected from substituted aryl and -N(Ra)C(O)Ra. In embodiments, R5cis selected from selected from unsubstituted or substituted alkynyl, substituted aryl, halo, -N(Ra)2, and - N(Ra)C(O)Ra. In embodiments, R5cis substituted aryl. In embodiments, the halo is Br. In embodiments, the substituted aryl is . In embodiments, the substituted aryl is . In embodiments, the substituted aryl is embodiments, -N(Ra)2, is -NH2.In embodiments, the alkynyl is optionally unsubstituted alkynyl. In embodiments, -N(Ra)C(O)Ra is . In embodiments, -N(Ra)C(O)Rais . In embodiments, R5b is embodiments, R5bis selected from , , , , embodiments, Alk is C1-C3alkyl. In embodiments, Alk is methyl. In embodiments, Alk is C1-C5alkyl substituted with aryl. In embodiments, Alk i In embodiments, R11aand R11bare each independently unsubstituted alkyl. In embodiments, R11aand R11bare each independently C1-C5alkyl. In embodiments, R11aand R11bare each independently C1-C3alkyl. In embodiments, R11aand R11bare each independently methyl. In embodiments, R11aand R11bare each independently , wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3-C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5 alkoxy, and n7 is an integer from 1 to 3, optionally n7 is 1 or 2. In embodiments, R11aand R11bare each independently selected from , In embodiments, R11aand R11bare each independently selected from

[0007] , , In embodiments, R11ais selected from H and unsubstituted alkyl, optionally methyl, and R11bis . In embodiments, R11ais selected from H and -CH3 and R11bis selected R11bis selected from , a embodiments, R11ais selected from H and -CH3and R11bis selected from In embodiments, the compound of formula (I) is a compound of formula (82): formula (82) wherein in formula (82): R11a, R11b,R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. In embodiments, the compound of formula (82) is a compound of formula (804) or (805):

[0008] In embodiments, the compound of formula (82) is a compound of formula (804), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (82) is a compound of formula (805), or a pharmaceutically acceptable salt thereof. In embodiments, R5band / or R5cis each independently -ORa, wherein Rais unsubstituted alkyl, optionally wherein - ORais -OCH3. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently cyclohexyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently alkyl substituted with cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently -CH2- substituted with cycloalkyl. In embodiments, R11aand R11care each hydrogen, R11band R11dare each independently . In embodiments, the compound of formula (800) or formula (801) is a compound of any one of formulas 1035-1037, 1040-1045, 1047-1051, 1053, 1055-1074, 1082, 1083, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (802) or formula (803) is a compound of any one of formulas 1046, 1052, 1054, 1075-1077, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (804) or formula (805) is a compound of formula 1072, 1073, or a pharmaceutically acceptable salt thereof. In embodiments, embodiments, the compound of formula (I) is a compound of formula (90): formula (90) wherein in formula (90): n is an integer from 1 to 5. In embodiments, the compound of formula (90) is a compound of formula (900), formula (901), or formula (902): In embodiments, the compound of formula (90) is a compound of formula (900), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (90) is a compound of formula (901), or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (90) is a compound of formula (902), or a pharmaceutically acceptable salt thereof. In embodiments, R12is H. In embodiments, R12is -CH3. In embodiments, R11ais H. In embodiments, R11ais substituted alkyl. In embodiments, R11ais alkyl substituted with aryl. In embodiments, embodiments, R10is -C(O)Ra. In embodiments, R10is -C(O)Rawherein Rais unsubstituted alkenyl. In embodiments, R10is . In embodiments, R10is -C(O)Rawherein Rais substituted alkyl. In embodiments, embodiments, R10is -C(O)Rawherein Rais substituted aryl. In embodiments, R10is embodiments, R10is -C(O)Rawherein Rais substituted heterocyclyl. In embodiments, R10is embodiments, R10is -S(O)tRa. In embodiments, R10is -S(O)tRawherein t is 2. In embodiments, R10is - S(O)tRawherein t is 2 and Rais substituted aryl. In embodiments, R10is 0 i In embodiments, the compound of formula (900), formula (901), or formula (902) is a compound of any one of formulas 1084-1098 or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of any one of formula 1002, 1005, 1010-1098, or a pharmaceutically acceptable salt thereof:

[0009] In embodiments, the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof:

[0010] In embodiments, embodiments, the compound of formula (I) is a compound of formula (40): wherein in formula (40): n4is an integer from 0 to 5. In embodiments, n4is 0. In embodiments, R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and unsubstituted or substituted alkyl. In embodiments, the alkyl is alkyl substituted with amido, and amido. In embodiments, R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and , wherein r is an integer from 0 to 4. In embodiments, r is 0. In embodiments, R6a, R6c, R6d, and R6eare each hydrogen. In embodiments, R6bis -C(O)NH2. In embodiments, A is . In embodiments, R8is unsubstituted or substituted aryl. In embodiments, the compound of formula (I) is a compound of formula (50): wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5 is an integer from 0 to 5; and t is 1 or 2. In embodiments, n5 is 3. In embodiments, R7a, R7b, R7c, R7d, R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, and halo. In embodiments, alkyl is -CH3. In embodiments, halo is F or Cl. In embodiments, R7a, R7b, R7c, and R7dare each hydrogen. In embodiments, R10a, R10b, R10d, and R10eare each hydrogen. In embodiments, R10cis F. In embodiments, A is . In embodiments, the compound of formula (I) is a compound of formula (60): formula (60) wherein in formula (60): n6is an integer from 0 to 5. In embodiments, n6is 1. In embodiments, R9is H. In embodiments, the compound of formula (I) is a compound of any one of formula 1001-1074, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition is formulated for parenteral administration. In embodiments, the pharmaceutical composition is formulated for topical, dermal, intradermal, intramuscular, intraperitoneal, intraarticular, intravenous, subcutaneous, intraarterial or transdermal administration. In embodiments, the pharmaceutical composition is formulated for topical administration. In embodiments, any of the Trim7 inhibitors disclosed herein (and / or additional agents) are included various formulations. Any Trim7 inhibitor (and / or additional agents) described herein can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In embodiments, the composition is in the form of a capsule (see, e.g., U.S. Patent No.5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington’s Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed.1995), incorporated herein by reference. In embodiments, the Trim7 inhibitor disclosed herein can possess a sufficiently basic functional group, which can react with an inorganic or organic acid, or a carboxyl group, which can react with an inorganic or organic base, to form a pharmaceutically acceptable salt. A pharmaceutically acceptable acid addition salt is formed from a pharmaceutically acceptable acid, as is well known in the art. Such salts include the pharmaceutically acceptable salts listed in, for example, Journal of Pharmaceutical Science, 66, 2-19 (1977) and The Handbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H. Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, which are hereby incorporated by reference in their entirety. In embodiments, the compositions disclosed herein are in the form of a pharmaceutically acceptable salt. Further, any Trim7 inhibitor disclosed herein can be administered to a subject as a component of pharmaceutical composition, that comprises a pharmaceutically acceptable carrier or vehicle. Such pharmaceutical compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient so as to provide the form for proper administration. Pharmaceutical excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be, for example, saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In embodiments, the pharmaceutically acceptable excipients are sterile when administered to a subject. Water is a useful excipient when any agent disclosed herein is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, specifically for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Any agent disclosed herein, if desired, can also comprise minor amounts of wetting or emulsifying agents, or pH buffering agents. The present disclosure includes the disclosed Trim7 inhibitor in various formulations of pharmaceutical composition. Any Trim7 inhibitor disclosed herein can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. DNA or RNA constructs encoding the protein sequences may also be used. In embodiments, the composition is in the form of a capsule (see, e.g., U.S. Patent No.5,698,155). Other examples of suitable pharmaceutical excipients are described in Remington’s Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed.1995), incorporated herein by reference. Where necessary, the pharmaceutical compositions comprising the Trim7 inhibitor can also include a solubilizing agent. Also, the agents can be delivered with a suitable vehicle or delivery device as known in the art. Combination therapies outlined herein can be co-delivered in a single delivery vehicle or delivery device. Pharmaceutical compositions for administration can optionally include a local anesthetic such as, for example, lignocaine to lessen pain at the site of the injection. The pharmaceutical compositions comprising the Trim7 inhibitor of the present disclosure may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing therapeutic agents into association with a carrier, which constitutes one or more accessory ingredients. Typically, the pharmaceutical compositions are prepared by uniformly and intimately bringing therapeutic agent into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into dosage forms of the desired formulation (e.g., wet or dry granulation, powder blends, etc., followed by tableting using conventional methods known in the art) In embodiments, any Trim7 inhibitor disclosed herein is formulated in accordance with routine procedures as a pharmaceutical composition adapted for a mode of administration disclosed herein. Administration, Dosing, and Treatment Regimens In one embodiment, any Trim7 inhibitor (and / or additional agents) described herein is formulated in accordance with routine procedures as a composition adapted for a mode of administration described herein. Routes of administration include, for example: intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. In embodiments, the administering is effected orally or by parenteral injection. In most instances, administration results in the release of any agent described herein into the bloodstream. Any Trim7 inhibitor (and / or additional agents) described herein can be administered orally. Such Trim7 inhibitors (and / or additional agents) can also be administered by any other convenient route, for example, by intravenous infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and can be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer. In specific embodiments, it may be desirable to administer locally to the area in need of treatment. In one embodiment, for instance in the treatment of cancer, the Trim7 inhibitor (and / or additional agents) are administered in the tumor microenvironment (e.g., cells, molecules, extracellular matrix and / or blood vessels that surround and / or feed a tumor cell, inclusive of, for example, tumor vasculature; tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelial progenitor cells (EPC); cancer-associated fibroblasts; pericytes; other stromal cells; components of the extracellular matrix (ECM); dendritic cells; antigen presenting cells; T-cells; regulatory T cells; macrophages; neutrophils; and other immune cells located proximal to a tumor) or lymph node and / or targeted to the tumor microenvironment or lymph node. In various embodiments, for instance in the treatment of cancer, the Trim7 inhibitor (and / or additional agents) are administered intratumorally. Dosage forms suitable for parenteral administration (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous and intra-articular injection and infusion) include, for example, solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions (e.g., lyophilized composition), which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art. The dosage of any Trim7 inhibitor (and / or additional agents) described herein as well as the dosing schedule can depend on various parameters, including, but not limited to, the disease being treated, the subject’s general health, and the administering physician’s discretion. Any Trim7 inhibitor described herein, can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concurrently with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of an additional agent, to a subject in need thereof. In various embodiments any Trim7 inhibitor and additional agent described herein are administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, 1 day apart, 2 days apart, 3 days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2 weeks apart, 3 weeks apart, or 4 weeks apart. In various embodiments, the current disclosure relates to the co-administration of a Trim7 inhibitor which induces an innate immune response and another Trim7 inhibitor which induces an adaptive immune response. In such embodiments, the Trim7 inhibitor which induces an innate immune response may be administered before, concurrently with, or subsequent to administration of the Trim7 inhibitor which induces an adaptive immune response. For example, the Trim7 inhibitors may be administered 1 minute apart, 10 minutes apart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, 1 day apart, 2 days apart, 3 days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2 weeks apart, 3 weeks apart, or 4 weeks apart. In an illustrative embodiment, the Trim7 inhibitor which induces an innate immune response and the Trim7 inhibitor which induces an adaptive response are administered 1 week apart, or administered on alternate weeks (i.e., administration of the Trim7 inhibitor inducing an innate immune response is followed 1 week later with administration of the Trim7 inhibitor which induces an adaptive immune response and so forth). The dosage of any Trim7 inhibitor (and / or additional agents) described herein can depend on several factors including the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the subject to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular subject may affect dosage used. Furthermore, the exact individual dosages can be adjusted somewhat depending on a variety of factors, including the specific combination of the agents being administered, the time of administration, the route of administration, the nature of the formulation, the rate of excretion, the particular disease being treated, the severity of the disorder, and the anatomical location of the disorder. Some variations in the dosage can be expected. For administration of any Trim7 inhibitor (and / or additional agents) described herein by parenteral injection, the dosage may be about 0.1 mg to about 250 mg per day, about 1 mg to about 20 mg per day, or about 3 mg to about 5 mg per day. Generally, when orally or parenterally administered, the dosage of any agent described herein may be about 0.1 mg to about 1500 mg per day, or about 0.5 mg to about 10 mg per day, or about 0.5 mg to about 5 mg per day, or about 200 to about 1,200 mg per day (e.g., about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg per day). In embodiments, administration of the Trim7 inhibitor (and / or additional agents) described herein is by parenteral injection at a dosage of about 0.1 mg to about 1500 mg per treatment, or about 0.5 mg to about 10 mg per treatment, or about 0.5 mg to about 5 mg per treatment, or about 200 to about 1,200 mg per treatment (e.g., about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about 1,200 mg per treatment). In embodiments, a suitable dosage of the Trim7 inhibitor (and / or additional agents) is in a range of about 0.01 mg / kg to about 100 mg / kg of body weight ,or about 0.01 mg / kg to about 10 mg / kg of body weight of the subject, for example, about 0.01 mg / kg, about 0.02 mg / kg, about 0.03 mg / kg, about 0.04 mg / kg, about 0.05 mg / kg, about 0.06 mg / kg, about 0.07 mg / kg, about 0.08 mg / kg, about 0.09 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.3 mg / kg, about 0.4 mg / kg, about 0.5 mg / kg, about 0.6 mg / kg, about 0.7 mg / kg, about 0.8 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1.1 mg / kg, about 1.2 mg / kg, about 1.3 mg / kg, about 1.4 mg / kg, about 1.5 mg / kg, about 1.6 mg / kg, about 1.7 mg / kg, about 1.8 mg / kg, 1.9 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg body weight, inclusive of all values and ranges therebetween. In another embodiment, delivery can be in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527- 1533; Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp.353-365 (1989)). Any Trim7 inhibitor (and / or additional agents) described herein can be administered by controlled-release or sustained- release means or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Patent Nos.3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,556, each of which is incorporated herein by reference in its entirety. Such dosage forms can be useful for providing controlled- or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Controlled- or sustained-release of an active ingredient can be stimulated by various conditions, including but not limited to, changes in pH, changes in temperature, stimulation by an appropriate wavelength of light, concentration or availability of enzymes, concentration or availability of water, or other physiological conditions or compounds. In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem.23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol.25:351; Howard et al., 1989, J. Neurosurg.71:105). In another embodiment, a controlled-release system can be placed in proximity of the target area to be treated, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Langer, 1990, Science 249:1527-1533 may be used. Administration of any Trim7 inhibitor (and / or additional agents) described herein can, independently, be one to four times daily or one to four times per month or one to six times per year or once every two, three, four or five years. Administration can be for the duration of one day or one month, two months, three months, six months, one year, two years, three years, and may even be for the life of the subject. The dosage regimen utilizing any Trim7 inhibitor (and / or additional agents) described herein can be selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the subject; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the subject; the pharmacogenomic makeup of the individual; and the specific compound of the disclosure employed. Any Trim7 inhibitor (and / or additional agents) described herein can be administered in a single daily dose, or the total daily dosage can be administered in divided doses of two, three or four times daily. Furthermore, any Trim7 inhibitor (and / or additional agents) described herein can be administered continuously rather than intermittently throughout the dosage regimen. Diseases; Methods of Treatment, and Patient Selections In one aspect, the present disclosure relates to a method for treating a cancer, an infectious disease, an inflammatory disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any of the embodiments disclosed herein. In embodiments, the cancer is selected from a basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post- transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs’ syndrome. In embodiments, the cancer is a hematologic cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt’s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin’s lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and pre-leukemia, or a combination thereof. In embodiments, the cancer is resistant to an anti-checkpoint agent. In embodiments, the anti-checkpoint agent is an antibody. In embodiments, the anti-checkpoint agent an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In embodiments, the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT- 011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). In embodiments, the infectious disease is a viral infection. In embodiments, the viral infection is caused by a virus selected from papilloma virus, herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis virus, Zika virus, Yellow Fever Virus, West Nile virus, Dengue virus, Japanese Encephalitis Virus, St. Louis Encephalitis Virus, Hepatitis C Virus, poliovirus, rhinovirus, enterovirus, coxsackievirus, influenza virus, lentivirus, respiratory syncytial virus, a human parainfluenza virus, rubulavirus (e.g., mumps virus), measles virus, human metapneumovirus, hantavirus, rotavirus, norovirus, and SARS virus (e.g., SARS-CoV-2). In embodiments, the inflammatory disease is an autoimmune disease or condition, selected from multiple sclerosis, diabetes mellitus, lupus, celiac disease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, scleroderms, Goodpasture's syndrome, Wegener's granulomatosis, autoimmune epilepsy, Rasmussen's encephalitis, Primary biliary sclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addison's disease, Hashimoto's thyroiditis, Fibromyalgia, Menier's syndrome; transplantation rejection (e.g., prevention of allograft rejection) pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, and other autoimmune disease. In one aspect, the present disclosure relates to a method for treating an anti-checkpoint agent-resistant cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any one of embodiments disclosed herein. In embodiments, the anti-checkpoint agent is an antibody. In embodiments, the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). In one aspect, the present disclosure relates to methods of treating viral infections including, without limitation, acute or chronic viral infections, for example, of the respiratory tract, of papilloma virus infections, of herpes simplex virus (HSV) infection, of human immunodeficiency virus (HIV) infection, and of viral infection of internal organs such as infection with hepatitis viruses. In embodiments, the viral infection is caused by a virus of family Flaviviridae. In embodiments, the virus of family Flaviviridae is selected from Zika virus, Yellow Fever Virus, West Nile virus, Dengue virus, Japanese Encephalitis Virus, St. Louis Encephalitis Virus, and Hepatitis C Virus. In embodiments, the viral infection is caused by a virus of family Picornaviridae, e.g., poliovirus, rhinovirus, enterovirus, coxsackievirus. In embodiments, the viral infection is caused by a member of Orthomyxoviridae, e.g., an influenza virus. In embodiments, the viral infection is caused by a member of Retroviridae, e.g., a lentivirus. In embodiments, the viral infection is caused by a member of Paramyxoviridae, e.g., respiratory syncytial virus, a human parainfluenza virus, rubulavirus (e.g., mumps virus), measles virus, and human metapneumovirus. In embodiments, the viral infection is caused by a member of Bunyaviridae, e.g., hantavirus. In embodiments, the viral infection is caused by a member of Reoviridae, e.g., a rotavirus. In one aspect, the present disclosure relates to methods of treating parasitic infections such as protozoan or helminths infections. In embodiments, the parasitic infection is by a protozoan parasite. In embodiments, the oritiziab parasite is selected from intestinal protozoa, tissue protozoa, or blood protozoa. Illustrative protozoan parasites include, but are not limited to, Entamoeba hystolytica, Giardia lamblia, Cryptosporidium muris, Trypanosomatida gambiense, Trypanosomatida rhodesiense, Trypanosomatida crusi, Leishmania mexicana, Leishmania braziliensis, Leishmania tropica, Leishmania donovani, Toxoplasma gondii, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, Trichomonas vaginalis, and Histomonas meleagridis. In embodiments, the parasitic infection is by a helminthic parasite such as nematodes (e.g., Adenophorea). In embodiments, the parasite is selected from Secementea (e.g., Trichuris trichiura, Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Wuchereria bancrofti, Dracunculus medinensis). In embodiments, the parasite is selected from trematodes (e.g. blood flukes, liver flukes, intestinal flukes, and lung flukes). In embodiments, the parasite is selected from: Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, Fasciola hepatica, Fasciola gigantica, Heterophyes, Paragonimus westermani. In embodiments, the parasite is selected from cestodes (e.g., Taenia solium, Taenia saginata, Hymenolepis nana, Echinococcus granulosus). In one aspect, the present disclosure relates to methods of treating bacterial infections. In embodiments, the bacterial infection is by gram-positive bacteria, gram-negative bacteria, aerobic and / or anaerobic bacteria. In embodiments, the bacteria is selected from, but not limited to, Staphylococcus, Lactobacillus, Streptococcus, Sarcina, Escherichia, Enterobacter, Klebsiella, Pseudomonas, Acinetobacter, Mycobacterium, Proteus, Campylobacter, Citrobacter, Nisseria, Baccillus, Bacteroides, Peptococcus, Clostridium, Salmonella, Shigella, Serratia, Haemophilus, Brucella and other organisms. In embodiments, the bacteria is selected from, but not limited to, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Burkholderia cepacia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Francisella tularensis, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter baumannii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Branhamella catarrhalis, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholerae, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Kingella, Moraxella, Gardnerella vaginalis, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Clostridium difficile, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, or Staphylococcus saccharolyticus. In one aspect, the present disclosure relates to methods of treating one or more autoimmune diseases or disorders. In embodiments, the treatment of an autoimmune disease or disorder may involve modulating the immune system with the present Trim7 inhibitors to favor immune inhibition over immune stimulation. Illustrative autoimmune diseases or disorders treatable with the present Trim7 inhibitors include those in which the body’s own antigens become targets for an immune response, such as, for example, rheumatoid arthritis, systemic lupus erythematosus, diabetes mellitus, ankylosing spondylitis, Sjögren's syndrome, inflammatory bowel diseases (e.g. colitis ulcerosa, Crohn's disease), multiple sclerosis, sarcoidosis, psoriasis, Grave's disease, Hashimoto's thyroiditis, psoriasis, hypersensitivity reactions (e.g., allergies, hay fever, asthma, and acute edema cause Type I hypersensitivity reactions), and vasculitis. Methods of Determining a Cancer Treatment for a Patient; Methods of Selecting a Patient for a Cancer Treatment; and Methods of Treatment In one aspect, the present disclosure relates to a method of determining a cancer treatment for a patient, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any embodiments disclosed herein, if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent. In embodiments, the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent. In embodiments, the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In one aspect, the present disclosure relates to a method for selecting a patient for a cancer treatment, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any embodiments disclosed herein, if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent. In embodiments, the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent. In embodiments, the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In one aspect, the present disclosure relates to a method of treating cancer, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) administering the pharmaceutical composition of any embodiments disclosed herein, if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally administering a second cancer therapy comprising an anti-checkpoint agent. In embodiments, the anti-checkpoint agent is selected from an anti-PD- 1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent. In embodiments, the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. In embodiments, the biological sample is a fresh tissue sample, frozen tumor tissue specimen, cultured cells, circulating tumor cells, or a formalin-fixed paraffin-embedded tumor tissue specimen. In embodiments, the biological sample is a biopsy sample, optionally wherein the biopsy sample is selected from endoscopic biopsy, bone marrow biopsy, endoscopic biopsy (e.g., cystoscopy, bronchoscopy and colonoscopy), needle biopsy (e.g., fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, X-ray-assisted biopsy, computerized tomography (CT)-assisted biopsy, magnetic resonance imaging (MRI)-assisted biopsy and ultrasound-assisted biopsy), skin biopsy (e.g., shave biopsy, punch biopsy, and incisional biopsy) and surgical biopsy. In embodiments, the biological sample comprises a body fluid selected from blood, plasma, serum, lacrimal fluid, tears, bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage such as a ductal lavage or broncheoalveolar lavage, aspirate, scraping, bone marrow specimen, tissue biopsy specimen, surgical specimen, feces, other body fluids, secretions, and / or excretions, and / or cells therefrom. In embodiments, the biological sample comprises at least one tumor cell. In embodiments, the evaluating is performed by DNA sequencing, RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof. In embodiments, the evaluating is performed by contacting the sample with an agent that specifically binds to Trim7. In embodiments, the agent that specifically binds to one or proteins comprises an antibody, antibody-like molecule or binding a fragment thereof. In embodiments, the evaluating is performed by contacting the sample with an agent that specifically binds to one or more of nucleic acids of Trim7. In embodiments, the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe. Combination Therapies and Conjugation In embodiments, the disclosure provides for Trim7 inhibitors and methods that further comprise administering an additional agent to a subject. In embodiments, the disclosure pertains to co-administration and / or co-formulation. Any of the compositions described herein may be co-formulated and / or co-administered. In embodiments, any Trim7 inhibitor described herein acts synergistically when co-administered with another agent and is administered at doses that are lower than the doses commonly employed when such agents are used as monotherapy. In embodiments, inclusive of, without limitation, cancer applications, the present disclosure pertains to chemotherapeutic agents as additional agents. Examples of chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and CYTOXAN cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (e.g., bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; cally statin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (e.g., cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB 1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo- 5-oxo-L-norleucine, ADRIAMYCIN doxorubicin (including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2- pyrrolino-doxorubicin and deoxy doxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as minoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, 111.), and TAXOTERE doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil; GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE. vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar, CPT-11) (including the treatment regimen of irinotecan with 5-FU and leucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; combretastatin; leucovorin (LV); oxaliplatin, including the oxaliplatin treatment regimen (FOLFOX); lapatinib (TYKERB); inhibitors of PKC-α, Raf, H-Ras, EGFR (e.g., erlotinib (Tarceva)) and VEGF-A that reduce cell proliferation and pharmaceutically acceptable salts, acids or derivatives of any of the above. In addition, the methods of treatment can further include the use of radiation. In addition, the methods of treatment can further include the use of photodynamic therapy. In embodiments, inclusive of, without limitation, cancer applications, the present additional agent is one or more immune-modulating agents selected from an agent that blocks, reduces and / or inhibits PD-1 and PD-L1 or PD-L2 and / or the binding of PD-1 with PD-L1 or PD-L2 (by way of non-limiting example, one or more of nivolumab (ONO- 4538 / BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB), pembrolizumab (KEYTRUDA, Merck), MK- 3475 (MERCK), BMS 936559 (BRISTOL MYERS SQUIBB), atezolizumab (TECENTRIQ, GENENTECH), MPDL328OA (ROCHE)), an agent that increases and / or stimulates CD137 (4-1BB) and / or the binding of CD137 (4- 1BB) with one or more of 4-1BB ligand (by way of non-limiting example, urelumab (BMS-663513 and anti-4-1BB antibody), and an agent that blocks, reduces and / or inhibits the activity of CTLA-4 and / or the binding of CTLA-4 with one or more of AP2M1, CD80, CD86, SHP-2, and PPP2R5A and / or the binding of OX40 with OX40L (by way of non- limiting example GBR 830 (GLENMARK), MEDI6469 (MEDIMMUNE). In embodiments, inclusive of, without limitation, infectious disease applications, the present disclosure pertains to anti- infectives as additional agents. In embodiments, the anti-infective is an anti-viral agent including, but not limited to, Abacavir, Acyclovir, Adefovir, Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine, Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide, Etravirine, Famciclovir, and Foscarnet. In embodiments, the anti- infective is an anti-bacterial agent including, but not limited to, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); monobactam antibiotics (aztreonam); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin, and meropenem). In embodiments, the anti-infectives include anti-malarial agents (e.g., chloroquine, quinine, mefloquine, primaquine, doxycycline, artemether / lumefantrine, atovaquone / proguanil and sulfadoxine / pyrimethamine), metronidazole, tinidazole, ivermectin, pyrantel pamoate, and albendazole. In embodiments, inclusive, without limitation, of autoimmune applications, the additional agent is an immunosuppressive agent. In embodiments, the immunosuppressive agent is an anti-inflammatory agent such as a steroidal anti-inflammatory agent or a non-steroidal anti-inflammatory agent (NSAID). Steroids, particularly the adrenal corticosteroids and their synthetic analogues, are well known in the art. Examples of corticosteroids useful in the present disclosure include, without limitation, hydroxyltriamcinolone, alpha-methyl dexamethasone, beta-methyl betamethasone, beclomethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, clobetasol valerate, desonide, desoxymethasone, dexamethasone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters, chloroprednisone, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate. (NSAIDS) that may be used in the present disclosure, include but are not limited to, salicylic acid, acetyl salicylic acid, methyl salicylate, glycol salicylate, salicylmides, benzyl-2,5-diacetoxybenzoic acid, ibuprofen, fulindac, naproxen, ketoprofen, etofenamate, phenylbutazone, and indomethacin. In embodiments, the immunosupressive agent may be cytostatics such as alkylating agents, antimetabolites (e.g., azathioprine, methotrexate), cytotoxic antibiotics, antibodies (e.g., basiliximab, daclizumab, and muromonab), anti-immunophilins (e.g., cyclosporine, tacrolimus, sirolimus), inteferons, opioids, TNF binding proteins, mycophenolates, and small biological agents (e.g., fingolimod, myriocin). In embodiments, inclusive, without limitation, the additional agent is a kras inhibitor (e.g. a kras G12C inhibitor). In embodiments, the kras inhibitor is selected from BI2865, MRTX113, sotorasib (AMG510), and adagrasib (MRTX849). In embodiments, inclusive, without limitation, the additional agent is a braf inhibitor. In embodiments, the braf inhibitor is selected from vemurafenib, dabrafenib and encorafenib. In embodiments, inclusive, without limitation, the additional agent is a MEK inhibitor. In embodiments, the MEK inhibitor is selected from binimetinib (MEK162), cobimetinib (XL518), selumetinib, and trametinib (GSK1120212). In embodiments, the Trim7 inhibitors (and / or additional agents) described herein, include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the composition such that covalent attachment does not prevent the activity of the composition. For example, but not by way of limitation, derivatives include composition that have been modified by, inter alia, glycosylation, lipidation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of turicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids. In still other embodiments, the Trim7 inhibitors (and / or additional agents) described herein further comprise a cytotoxic agent, comprising, in illustrative embodiments, a toxin, a chemotherapeutic agent, a radioisotope, and an agent that causes apoptosis or cell death. Such agents may be conjugated to a composition described herein. The Trim7 inhibitors (and / or additional agents) described herein may thus be modified post-translationally to add effector moieties such as chemical linkers, detectable moieties such as for example fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties, or functional moieties such as for example streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, and radioactive materials. Subjects and / or Animals In embodiments, the subject and / or animal is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep, or non-human primate, such as a monkey, chimpanzee, or baboon. In embodiments, the subject and / or animal is a non-mammal, such, for example, a zebrafish. In embodiments, the subject and / or animal may comprise fluorescently-tagged cells (with e.g. GFP). In embodiments, the subject and / or animal is a transgenic animal comprising a fluorescent cell. In embodiments, the subject and / or animal is a human. In embodiments, the human is a pediatric human. In embodiments, the human is an adult human. In embodiments, the human is a geriatric human. In embodiments, the human may be referred to as a patient. In certain embodiments, the human has an age in a range of from about 0 months to about 6 months old, from about 6 to about 12 months old, from about 6 to about 18 months old, from about 18 to about 36 months old, from about 1 to about 5 years old, from about 5 to about 10 years old, from about 10 to about 15 years old, from about 15 to about 20 years old, from about 20 to about 25 years old, from about 25 to about 30 years old, from about 30 to about 35 years old, from about 35 to about 40 years old, from about 40 to about 45 years old, from about 45 to about 50 years old, from about 50 to about 55 years old, from about 55 to about 60 years old, from about 60 to about 65 years old, from about 65 to about 70 years old, from about 70 to about 75 years old, from about 75 to about 80 years old, from about 80 to about 85 years old, from about 85 to about 90 years old, from about 90 to about 95 years old or from about 95 to about 100 years old. In embodiments, the subject is a non-human animal, and therefore the disclosure pertains to veterinary use. In a specific embodiment, the non-human animal is a household pet. In another specific embodiment, the non-human animal is a livestock animal. Kits The disclosure provides kits that can simplify the administration of any agent described herein. An illustrative kit of the disclosure comprises any composition described herein in unit dosage form. In one embodiment, the unit dosage form is a container, such as a pre-filled syringe, which can be sterile, containing any agent described herein and a pharmaceutically acceptable carrier, diluent, excipient, or vehicle. The kit can further comprise a label or printed instructions instructing the use of any agent described herein. The kit may also include a lid speculum, topical anesthetic, and a cleaning agent for the administration location. The kit can also further comprise one or more additional agent described herein. In one embodiment, the kit comprises a container containing an effective amount of a composition of the disclosure and an effective amount of another composition, such those described herein. The instant disclosure also provides certain embodiments as follows: Embodiment 1. A compound of formula (I), or a pharmaceutically acceptable salt thereof: formula (I) wherein in formula (I): , L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1 is an integer from 0 to 5; t is 1 or 2; with the proviso that the compound of formula (I) is not a compound of any one of formulas 1001, 1003, 1004, and 1006-1009: Embodiment 2. The compound of Embodiment 1, wherein R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, optionally substituted with halo, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -C(O)Ra, -C(O)N(Ra)2, -N(Ra)2, -N(Ra)C(O)Ra, and -S(O)tRa. Embodiment 3. The compound of Embodiment 1 or 2, wherein L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10 cycloalkenyl-, -C1-10 alkynyl-, -O-C1-10 alkynyl-, -C1-10 aryl-, -O-C1-10-, -aryl-,-cycloalkyl-, - heterocyclyl-, -O-, -S-, -S-S-, -S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, - N(Rb)C(O)-, -OC(O)N(Rb)-, -N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, - N(Rb)S(O)w-, -S(O)wN(Rb)-, -S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O- )3, wherein w is 1 or 2, and Rbis independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, optionally L is a bond and / or -C(O)- and / or -C(H)(CH2)pC(O)NH2, and / or , wherein p is an integer from 1-5, optionally p is 2; optionally L is wherein the alkyl is substituted or unsubstituted, Embodiment 4. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (10): wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2 is an integer from 0 to 5; and t is 1 or 2. Embodiment 5. The compound of Embodiment 4, wherein n2is 2. Embodiment 6. The compound of Embodiment 4 or 5, wherein R1ais C1-6 alkyl, optionally -CH3. Embodiment 7. The compound of any one of Embodiments 4-6, wherein R2is H. Embodiment 8. The compound of any one of Embodiments 4-7, wherein R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen and halo, optionally F or Cl. Embodiment 9. The compound of any one of Embodiments 4-8, wherein R9a, R9b, R9c, R9d, and R9eare each hydrogen. Embodiment 10. The compound of any one of Embodiments 4-8, wherein R9a, R9d, and R9eare each hydrogen, optionally wherein R9bis Cl and / or R9cis F. Embodiment 11. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (20) or (21): wherein in formula (20) and (21): n3is an integer from 0 to 5. Embodiment 12. The compound of Embodiment 11, wherein n3is 2. Embodiment 13. The compound of Embodiment 11 or 12, wherein R4ais H. Embodiment 14. The compound of any one of Embodiments 11-13, wherein R4bis H. Embodiment 15. The compound of any one of Embodiments 11-13, wherein R3is C1-6 alkyl, optionally -CH3. Embodiment 16. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (30) or (31): wherein in formula (30) and (31): p is an integer from 0 to 5. Embodiment 17. The compound of Embodiment 16, wherein p is 2. Embodiment 18. The compound of Embodiment 16 or 17, wherein R5a, R5b, R5c, R5d, and R5eare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 19. The compound of any one of Embodiments 16-18, wherein R5a, R5c, R5d, and R5eare each hydrogen, optionally wherein R5dis -CH3. Embodiment 20. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (32): wherein in formula (32): q is an integer from 1 to 3. Embodiment 21. The compound of Embodiment 20, wherein q is 1. Embodiment 22. The compound of Embodiment 20 or 21, wherein R5a, R5b, R5c, and R5dare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 23. The compound of any one of Embodiments 19-21, wherein R5a, R5b, R5c, and R5dare each hydrogen. Embodiment 24. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (40): wherein in formula (40): n4is an integer from 0 to 5. Embodiment 25. The compound of Embodiment 24, wherein n4is 0. Embodiment 26. The compound of Embodiment 24 or 25, wherein R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and unsubstituted or substituted alkyl, optionally alkyl substituted with amido, and amido. Embodiment 27. The compound of any one of Embodiments 24-26, wherein R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and , wherein r is an integer from 0 to 4, optionally r is 0. Embodiment 28. The compound of any one of Embodiments 24-27, wherein R6a, R6c, R6d, and R6eare each hydrogen, optionally R6bis -C(O)NH2. Embodiment 29. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (50): wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5 is an integer from 0 to 5; and t is 1 or 2. Embodiment 30. The compound of Embodiment 29, wherein n5 is 3. Embodiment 31. The compound of Embodiment 29 or 30, wherein R7a, R7b, R7c, R7d, R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 32. The compound of any one of Embodiments 29-31, wherein R7a, R7b, R7c, and R7dare each hydrogen. Embodiment 33. The compound of any one of Embodiments 29-31, wherein R10a, R10b, R10d, and R10eare each hydrogen, optionally wherein R10cis F. Embodiment 34. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (60): wherein in formula (60): n6is an integer from 0 to 5. Embodiment 35. The compound of Embodiment 34, wherein n6is 1. Embodiment 36. The compound of Embodiment 34, wherein R9is H. Embodiment 37. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (70): wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 38. The compound of Embodiment 37, wherein the compound of formula (70) is a compound of formula (700) or (701): Embodiment 39. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (80) or formula (81): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8 is an integer from 1 to 5; wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 40. The compound of Embodiment 39, wherein the compound of formula (80) is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803): Formula (802) formula (803). Embodiment 41. The compound of Embodiment 37 or 39, wherein R5aand R5dare each hydrogen. Embodiment 42. The compound of any one of Embodiments 37-41, wherein R5band / or R5cis each independently selected from unsubstituted or substituted alkynyl, optionally substituted alkynyl, substituted aryl, substituted , , , d , . Embodiment 43. The compound of any one of Embodiments 37-42, wherein R11aand R11bare each unsubstituted alkyl, or R11aand R11bare each independently , or R11ais selected from H and unsubstituted alkyl and R11b is , or R11ais H and R11bis unsubstituted alkyl, wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3-C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7is 1 or 2. Embodiment 44. The compound of Embodiment 43, wherein R11aand R11bare each independently selected from d , Embodiment 45. The compound of Embodiment 43, wherein R11ais selected from H and -CH3 and R11bis selected f , , Embodiment 46. The compound of Embodiment 43, wherein R11ais selected from H and -CH3 and R11bis selected f Embodiment 47. The compound of Embodiment 43, wherein R11ais H and R11bis -CH3or wherein R11aand R11bare each -CH3. Embodiment 48. The compound of any one of Embodiments 39-47, wherein n8 is 1. Embodiment 49. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (82): formula (82) wherein in formula (82): R11a, R11b, R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 50. The compound of Embodiment 49, wherein the compound of formula (82) is a compound of formula (804) or (805): Embodiment 51. The compound of Embodiment 49 or 50, wherein R5band / or R5cis each independently -ORa, wherein Rais unsubstituted alkyl, optionally wherein -ORais -OCH3. Embodiment 52. The compound of any one of Embodiments 49-51, wherein R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl, optionally cyclohexyl; or R11aand R11care each hydrogen, R11band R11dare each independently alkyl substituted with cycloalkyl, optionally . Embodiment 53. The compound of any one of Embodiments 1-3, wherein the compound of formula (I) is a compound of formula (90): formula (90) wherein in formula (90): n is an integer from 1 to 5. Embodiment 54. The compound of Embodiment 53, wherein the compound of formula (90) is a compound of formula (900). formula (901), or formula (902): Embodiment 55. The compound of Embodiment 53 or 54, wherein R12is H or -CH3. Embodiment 56. The compound of any one of Embodiments 53-55, wherein R11ais H or substituted alkyl, optionally Embodiment 57. The compound of any one of Embodiments 53-56, wherein R10is -C(O)Ra, optionally wherein Rais selected from unsubstituted alkenyl, substituted alkyl, substituted aryl, and substituted heterocyclyl, or R10is -S(O)tRa, optionally wherein t is 2 and Rais substituted aryl. Embodiment 58. The compound of any one of Embodiments 53-57, wherein R10is selected from:

[0011] Embodiment 59. The compound of any one of Embodiments 1-3 or 37-58, wherein the compound of formula (I) is a compound of any one of formula 1002, 1005, 1010-1098, or a pharmaceutically acceptable salt thereof: Embodiment 60. The compound of any one of Embodiments 1-3 or 37-59, wherein the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof: Embodiment 61. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient: formula (I) wherein in formula (I): , L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9,R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1is an integer from 0 to 5; and t is 1 or 2. Embodiment 62. The pharmaceutical composition of Embodiment 61, wherein R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, optionally substituted with halo, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, -N(Ra)2, -C(O)Ra, -C(O)N(Ra)2, -N(Ra)C(O)Ra, and -S(O)tRa. Embodiment 63. The pharmaceutical composition of Embodiment 61 or 62, wherein L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10cycloalkenyl-, -C1-10alkynyl-, -O-C1-10alkynyl-, -C1-10aryl-, -O-C1-10-, -aryl-,- cycloalkyl-, -heterocyclyl-, -O-, -S-, -S-S-, -S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, - C(O)N(Rb)-, -N(Rb)C(O)-, -OC(O)N(Rb)-, -N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, - N(Rb)C(NRb)N(Rb)-, -N(Rb)S(O)w-, -S(O)wN(Rb)-, -S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, - O(S)P(ORb)O-, and (S)P(O-)3, wherein w is 1 or 2, and Rbis independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, optionally L is a bond and / or -C(O)- and / or -C(H)(CH2)pC(O)NH2, and / or , wherein p is an integer from 1-5, optionally p is 2, optionally L is wherein the alkyl is substituted or unsubstituted, . Embodiment 64. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (10): formula (10) wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2is an integer from 0 to 5; and t is 1 or 2. Embodiment 65. The pharmaceutical composition of Embodiment 64, wherein n2is 2. Embodiment 66. The pharmaceutical composition of Embodiment 64 or 65, wherein R1ais C1-6alkyl, optionally -CH3. Embodiment 67. The pharmaceutical composition of any one of Embodiments 64-66, wherein R2is H. Embodiment 68. The pharmaceutical composition of any one of Embodiments 64-67, wherein R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen and halo, optionally F or Cl. Embodiment 69. The pharmaceutical composition of any one of Embodiments 64-68, wherein R9a, R9b, R9c, R9d, and R9eare each hydrogen. Embodiment 70. The pharmaceutical composition of any one of Embodiments 64-69, wherein R9a, R9d, and R9eare each hydrogen, optionally wherein R9bis Cl and / or R9cis F. Embodiment 71. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (20) or (21): wherein in formula (20) and (21): n3 is an integer from 0 to 5. Embodiment 72. The pharmaceutical composition of Embodiment 71, wherein n3 is 2. Embodiment 73. The pharmaceutical composition of Embodiment 71 or 72, wherein R4ais H. Embodiment 74. The pharmaceutical composition of any one of Embodiments 71-73, wherein R4bis H. Embodiment 75. The pharmaceutical composition of any one of Embodiments 71-74, wherein R3is C1-6alkyl, optionally -CH3. Embodiment 76. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (30) or (31):

[0012] wherein in formula (30) and (31): p is an integer from 0 to 5. Embodiment 77. The pharmaceutical composition of Embodiment 76, wherein p is 2. Embodiment 78. The pharmaceutical composition of Embodiment 76 or 77, wherein R5a, R5b, R5c, R5d, and R5eare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 79. The pharmaceutical composition of any one of Embodiments 76-78, wherein R5a, R5c, R5d, and R5eare each hydrogen, optionally wherein R5dis -CH3. Embodiment 80. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (32): wherein in formula (32): q is an integer from 1 to 3. Embodiment 81. The pharmaceutical composition of Embodiment 80, wherein q is 1. Embodiment 82. The pharmaceutical composition of Embodiment 80 or 81, wherein R5a, R5b, R5c, and R5dare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 83. The pharmaceutical composition of any one of Embodiments 80-82, wherein R5a, R5b, R5c, and R5dare each hydrogen. Embodiment 84. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (40): formula (40) wherein in formula (40): n4 is an integer from 0 to 5. Embodiment 85. The pharmaceutical composition of Embodiment 84, wherein n4is 0. Embodiment 86. The pharmaceutical composition of Embodiment 84 or 85, wherein R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and unsubstituted or substituted alkyl, optionally alkyl substituted with amido, and amido. Embodiment 87. The pharmaceutical composition of any one of Embodiments 84-86, wherein R6a, R6b, R6c, R6d, and R6eare each independently selected from hydrogen and , wherein r is an integer from 0 to 4, optionally r is 0. Embodiment 88. The pharmaceutical composition of any one of Embodiments 84-87, wherein R6a, R6c, R6d, and R6eare each hydrogen, optionally R6bis -C(O)NH2. Embodiment 89. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (50): formula (50) wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5is an integer from 0 to 5; and t is 1 or 2. Embodiment 90. The pharmaceutical composition of Embodiment 89, wherein n5 is 3. Embodiment 91. The pharmaceutical composition of Embodiment 89 or 90, wherein R7a, R7b, R7c, R7d, R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, optionally -CH3, and halo, optionally F or Cl. Embodiment 92. The pharmaceutical composition of any one of Embodiments 89-91, wherein R7a, R7b, R7c, and R7dare each hydrogen. Embodiment 93. The pharmaceutical composition of any one of Embodiments 89-92, wherein R10a, R10b, R10d, and R10eare each hydrogen, optionally wherein R10cis F. Embodiment 94. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (60): formula (60) wherein in formula (60): n6 is an integer from 0 to 5. Embodiment 95. The pharmaceutical composition of Embodiment 94, wherein n6is 1. Embodiment 96. The pharmaceutical composition of Embodiment 94 or 95, wherein R9is H. Embodiment 97. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (70): formula (70) wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 98. The pharmaceutical composition of Embodiment 97, wherein the compound of formula (70) is a compound of formula (700) or (701): formula (700) formula (701). Embodiment 99. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (80) or formula (81): wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8 is an integer from 1 to 5; wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 100. The pharmaceutical composition of Embodiment 99, wherein the compound of formula (80) is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803): Formula (802) formula (803). Embodiment 101. The pharmaceutical composition of Embodiment 97 or 99, wherein R5aand R5dare each hydrogen. Embodiment 102. The pharmaceutical composition of any one of Embodiments 97-101, wherein R5band / or R5cis each independently selected from unsubstituted or substituted alkynyl, optionally substituted alkynyl, substituted aryl, , , , d , . Embodiment 103. The pharmaceutical composition of any one of Embodiments 97-102, wherein R11aand R11bare each unsubstituted alkyl, or R11aand R11bare each independently , or R11ais selected from H and unsubstituted alkyl and R11bis , or R11ais H and R11bis unsubstituted alkyl, wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3- C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7is 1 or 2. Embodiment 104. The pharmaceutical composition of Embodiment 103, wherein R11aand R11bare each independently s , , Embodiment 105. The pharmaceutical composition of Embodiment 103, wherein R11ais selected from H and -CH3and R11bis selected f , d f Embodiment 106. The pharmaceutical composition of Embodiment 103, wherein R11ais H and R11bis -CH3 or wherein R11aand R11bare each -CH3. Embodiment 107. The pharmaceutical composition of any one of Embodiments 103-106, wherein n8 is 1. Embodiment 108. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (82): formula (82) wherein in formula (82): R11a, R11b,R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl. Embodiment 109. The pharmaceutical composition of Embodiment 108, wherein the compound of formula (82) is a compound of formula (804) or (805): Embodiment 110. The pharmaceutical composition of Embodiment 108 or 109, wherein R5band / or R5cis each independently -ORa, wherein Rais unsubstituted alkyl, optionally wherein -ORais -OCH3. Embodiment 111. The pharmaceutical composition of any one of Embodiments 108-110, wherein R11aand R11care each hydrogen, R11band R11dare each independently unsubstituted cycloalkyl, optionally cyclohexyl; or R11aand R11care each hydrogen, R11band R11dare each independently alkyl substituted with cycloalkyl, optionally . Embodiment 112. The pharmaceutical composition of any one of Embodiments 61-63, wherein the compound of formula (I) is a compound of formula (90): formula (90) wherein in formula (90): n is an integer from 1 to 5. Embodiment 113. The pharmaceutical composition of Embodiment 112, wherein the compound of formula (90) is a compound of formula (900), formula (901), or formula (902): Embodiment 114. The pharmaceutical composition of Embodiment 112 or 113, wherein R12is H or -CH3. Embodiment 115. The pharmaceutical composition of any one of Embodiments 112-114, wherein R11ais H or substituted alkyl, optionally Embodiment 116. The pharmaceutical composition of any one of Embodiments 112-115, wherein R10is -C(O)Ra, optionally wherein Rais selected from unsubstituted alkenyl, substituted alkyl, substituted aryl, and substituted heterocyclyl, or R10is -S(O)tRa, optionally wherein t is 2 and Rais substituted aryl. Embodiment 117. The pharmaceutical composition of any one of Embodiments 112-116, wherein R10is selected from:

[0013] Embodiment 118. The pharmaceutical composition of Embodiment 61, wherein the compound of formula (I) is a compound of any one of formula 1001-1098, or a pharmaceutically acceptable salt thereof: Embodiment 119. The pharmaceutical composition of Embodiment 61, wherein the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof: Embodiment 120. A method for treating a cancer, an infectious disease, an inflammatory disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any one of Embodiments 61-119. Embodiment 121. The method of Embodiment 120, wherein the cancer is selected from a basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin's and non-Hodgkin's lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs’ syndrome. Embodiment 122. The method of Embodiment 120 or 121, wherein the cancer is a hematologic cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt’s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin’s lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and pre-leukemia, or a combination thereof. Embodiment 123. The method of any one of Embodiments 120-122, wherein the cancer is resistant to an anti- checkpoint agent. Embodiment 124. The method of any one of Embodiments 120-123, wherein the anti-checkpoint agent is an antibody, optionally selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and anti-CTLA antibody. Embodiment 125. The method of Embodiment 124, wherein the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). Embodiment 126. The method of Embodiment 120, wherein the infectious disease is a viral infection. Embodiment 127. The method of Embodiment 126, wherein the viral infection is caused by a virus selected from papilloma virus, herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis virus, Zika virus, Yellow Fever Virus, West Nile virus, Dengue virus, Japanese Encephalitis Virus, St. Louis Encephalitis Virus, Hepatitis C Virus, poliovirus, rhinovirus, enterovirus, coxsackievirus, influenza virus, lentivirus, respiratory syncytial virus, a human parainfluenza virus, rubulavirus (e.g., mumps virus), measles virus, human metapneumovirus, hantavirus, rotavirus, norovirus, and SARS virus (e.g., SARS-CoV-2). Embodiment 128. The method of Embodiment 120, wherein the inflammatory disease is an autoimmune disease or condition, selected from multiple sclerosis, diabetes mellitus, lupus, celiac disease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome, scleroderms, Goodpasture's syndrome, Wegener's granulomatosis, autoimmune epilepsy, Rasmussen's encephalitis, Primary biliary sclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addison's disease, Hashimoto's thyroiditis, Fibromyalgia, Menier's syndrome; transplantation rejection (e.g., prevention of allograft rejection) pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, and other autoimmune disease. Embodiment 129. A method for treating an anti-checkpoint agent-resistant cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any one of Embodiments 61-119. Embodiment 130. The method of Embodiment 129, wherein the anti-checkpoint agent is an antibody, optionally selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and anti-CTLA antibody. Embodiment 131. The method of Embodiment 130, wherein the antibody is selected from nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559, MPDL328OA (ROCHE), Cemiplimab (LIBTAYO), Atezolizumab (TECENTRIQ), Avelumab (BAVENCIO), and Durvalumab (IMFINZI). Embodiment 132. A method of determining a cancer treatment for a patient, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any one of Embodiments 61- 119 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. Embodiment 133. A method for selecting a patient for a cancer treatment, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any one of Embodiments 61- 119 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. Embodiment 134. A method of treating cancer, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) administering the cancer therapy comprising the pharmaceutical composition of any one of Embodiments 61-119 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti- checkpoint agent; and (d) optionally administering a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody. Embodiment 135. The method of any one of Embodiments 132-134, wherein the biological sample is a fresh tissue sample, frozen tumor tissue specimen, cultured cells, circulating tumor cells, or a formalin-fixed paraffin-embedded tumor tissue specimen. Embodiment 136. The method of any one of Embodiments 132-135, wherein the biological sample is a biopsy sample, optionally wherein the biopsy sample is selected from endoscopic biopsy, bone marrow biopsy, endoscopic biopsy (e.g., cystoscopy, bronchoscopy and colonoscopy), needle biopsy (e.g., fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, X-ray-assisted biopsy, computerized tomography (CT)-assisted biopsy, magnetic resonance imaging (MRI)-assisted biopsy and ultrasound-assisted biopsy), skin biopsy (e.g., shave biopsy, punch biopsy, and incisional biopsy) and surgical biopsy. Embodiment 137. The method of any one of Embodiments 132-136, wherein the biological sample comprises a body fluid selected from blood, plasma, serum, lacrimal fluid, tears, bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy sample, cell-containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage such as a ductal lavage or broncheoalveolar lavage, aspirate, scraping, bone marrow specimen, tissue biopsy specimen, surgical specimen, feces, other body fluids, secretions, and / or excretions, and / or cells therefrom. Embodiment 138. The method of any one of Embodiments 132-137, wherein the biological sample comprises at least one tumor cell. Embodiment 139. The method of any one of Embodiments 132-138, wherein the evaluating is performed by DNA sequencing, RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof. Embodiment 140. The method of any one of Embodiments 132-139, wherein the evaluating is performed by contacting the sample with an agent that specifically binds to Trim7. Embodiment 141. The method of Embodiment 140, wherein the agent that specifically binds to one or proteins comprises an antibody, antibody-like molecule or binding a fragment thereof. Embodiment 142. The method of any one of Embodiments 132-141, wherein the evaluating is performed by contacting the sample with an agent that specifically binds to one or more of nucleic acids of Trim7. Embodiment 143. The method of Embodiment 142, wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe. Any aspect or embodiment described herein can be combined with any other aspect or embodiment as disclosed herein The disclosure will be further described in the following examples, which do not limit the scope of the disclosure described in the claims. EXAMPLES The examples herein are provided to illustrate advantages and benefits of the present disclosure and to further assist a person of ordinary skill in the art with preparing or using the Trim7 inhibitors of the present disclosure. The examples herein are also presented in order to more fully illustrate the preferred aspects of the present disclosure. The examples should in no way be construed as limiting the scope of the present disclosure, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects or embodiments of the present disclosure described above. The variations, aspects or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present disclosure. Example 1: Binding of Recombinant Human Trim7 Protein to RACO1 and MSK1 Without wishing to be bound by theory, it is believed that MSK1 directly phosphorylates the tripartite motif containing 7 (Trim7). It is believed, without wishing to be bound by theory, that Trim7 can ubiquitinylate proteins such as RACO1, Mitochondrial Anti-Viral Signaling Protein (MAVS) and STING, which in turn impairs host immune interferon responsiveness. The binding of Trim7 protein to RACO1 and MSK1 was studied using a Meso Scale Discovery (MSD) platform-based assay. Briefly, recombinant human Trim7 protein was coated on a plate. Increasing amounts of RACO1, MSK1, or CD47 proteins were added to the plate for capture by the plate-bound recombinant Trim7 protein. The RACO1 or MSK1 proteins captured by the plate-bound Trim7 protein was detected using an anti-human RACO1 o anti-human MSK1 antibodies and a SULFO-TAG conjugated secondary antibody. As shown in FIG.1A, RACO1 protein bound to the plate-bound recombinant Trim7 protein in a dose-dependent manner. In comparison, the CD47 protein showed only background signal (FIG.1A). similarly, as shown in FIG.1B, MSK1 protein bound to the plate-bound recombinant Trim7 protein in a dose-dependent manner. In comparison, the CD47 protein showed only background signal (FIG. 1B). These results demonstrate, inter alia, that the Trim7 protein disclosed herein specifically binds to RACO1, MSK1 proteins. Example 2: Binding of Recombinant Human Trim7 Protein to Enterovirus 712BC Protein The binding of Trim7 protein to enterovirus 712B / C and 2C proteins was studied using a Meso Scale Discovery (MSD) platform-based assay. For this experiment, recombinant human RACO1 and MSK1 proteins were used as positive controls and recombinant human CD47 protein was used as a negative control. Briefly, recombinant human RACO1, MSK1, CD47, enterovirus 712B or enterovirus 712BC proteins were coated on a plate. Increasing amounts of recombinant human Trim7 protein was added to the plate for capture by the plate-bound RACO1, MSK1, CD47, enterovirus 712B or enterovirus 712BC proteins. The Trim7 protein captured by the plate-bound RACO1, MSK1, CD47, enterovirus 712B or enterovirus 712BC proteins was detected using an anti-human Trim7 antibody and a SULFO-TAG conjugated secondary antibody. As shown in FIG.2, Trim7 was able to bind the plate-bound enterovirus 712B / C protein in a dose-dependent manner. As expected, Trim7 was able to bind the plate-bound RACO1 and MSK1 proteins, but not CD47 protein (FIG.2). The extent of binding of Trim7 to enterovirus 712B / C protein approximated the levels of binding to MSK1 and RACO1. In comparison, Trim7 did not noticeably bind to the 2B portion of the viral protein (FIG.2). These results demonstrate, inter alia, that the Trim7 protein disclosed herein specifically binds to enterovirus 712B / C protein. Example 3: Enterovirus 712BC Protein Disrupts the Binding of Recombinant Human Trim7 Protein to RACO1 and MSK1 The effect of enterovirus 712B / C protein on the binding of Trim7 protein to recombinant human RACO1 or MSK1 proteins was studied using an a Meso Scale Discovery (MSD) platform-based assay. Briefly, recombinant human Trim7 protein was coated on a plate. Increasing amounts of enterovirus 712B / C protein was added to the plate for capture by the plate-bound recombinant Trim7 protein. Recombinant human MSK1 protein was added to the plate with or without 5 μg / ml enterovirus 712B / C protein. The binding was then detected using anti- MSK1 antibody and a SULFO- TAG conjugated secondary antibody. As shown in FIG.3A, Trim7 could be detected with MSK1 protein / anti- MSK1 antibody. Interestingly, the amount of signal reduced when the detection was performed in the presence of 5 μg / ml enterovirus 712B / C protein (FIG.3A). These results demonstrate, inter alia, that enterovirus 712BC protein disrupts the binding of recombinant human Trim7 protein to MSK1. In another such experiment, recombinant human Trim7 protein was coated on a plate. Increasing amounts of enterovirus 712B / C protein was added to the plate for capture by the plate-bound recombinant Trim7 protein. Recombinant human RACO1 protein was added to the plate with or without 5 μg / ml enterovirus 712B / C protein. The binding was then detected using anti- RACO1 antibody and a SULFO-TAG conjugated secondary antibody. As shown in FIG.3B, Trim7 could be detected with RACO1 protein / anti-RACO1 antibody. Interestingly, the amount of signal reduced when the detection was performed in the presence of 5 μg / ml enterovirus 712B / C protein (FIG.3B). These results demonstrate, inter alia, that enterovirus 712BC protein disrupts the binding of recombinant human Trim7 protein to RACO1. Example 4: Identification of Trim7 Inhibitors Based on Molecular Modeling The crystal structure of Trim7 has been solved. Muñoz Sosa, et al., Crystal structure and mutational analysis of the human Trim7 B30.2 domain provide insights into the molecular basis of its binding to glycogenin-1, J Biol Chem 2021;296:100772. The crystal structure has malonic acid bound to a pocket. The crystal structure of Trim7 bound to the CVB_2C (319-329) peptide (SVGTTLEALFQ) has also been solved. Liang et al., Structural insights into the viral proteins binding by Trim7 reveal a general C-terminal glutamine recognition mechanism, bioRxiv 2022.03.24.485560. FIG.4 (left top panel) shows a schematic representation of the CVB3 C2 protein, showing the location of the CVB_2C (319-329) peptide. FIG.4 (left bottom panel) shows crystal structure of CVB_2C protein, showing the CVB_2C (319- 329) peptide, and a crystal structure of the Trim7 protein complexed with the CVB_2C (319-329) peptide. FIG.4 (right panel) shows the interactions of the CVB_2C (319-329) peptidewith various amino acids of Trim7 protein. This crystal structure shows that glutamine-specific interaction is observed with the CVB3_2C peptide, which is inserted into a positively charged groove of the Trim7 PRY-SPRY domain. A homology models of Trim7 with CVB3_2C peptide (TTLEALFQ), GNI peptide (RKLDTYLQ) or a shortened peptide (Ac-ALFQ) were developed based on available crystal structures. Homology models revealed interaction of carboxy- group of the C-terminal glutamine of CVB3_2C peptide with Trim7 protein (FIG.5). Additional hydrophobic interactions with Phe or Leu at second-last amino acid were also observed (FIG.5). Based on these interactions, conformationally restrained, rigid small compounds containing carboxy group and certain aromatic moieties that dock well in the molecule were identified, which included the compounds of formula (I). FIG.5 shows a schematic representation of the molecular simulation-based method used for identification of Trim7 inhibitors, including compound of formula 1. FIG.6 shows various docked compounds. The underlined compounds have a docking score better than -7, indicative of likely affinity constant of <100nM. Representative compounds along with their docking scores are shown in FIG.7. Based on this model, compound 1001 can bind to Trim7 (FIG.8A). this binding is stabilized by hydrophobic stacking interactions, among others (FIG.8B). These results demonstrate, inter alia, that the compounds of formula (I) are likely to disrupt the binding of recombinant human Trim7 protein to MSK1. Accordingly, the compounds of formula (I) are inhibitors of Trim7, which are useful in the methods disclosed herein. Example 5: Disruption of the Binding of Recombinant Human Trim7 Protein to RACO1 and MSK1 The effect of compounds of formula (I) on the binding of Trim7 protein to recombinant human RACO1 or MSK1 proteins is studied using an a Meso Scale Discovery (MSD) platform-based assay. Briefly, recombinant human Trim7 protein is coated on a plate. Increasing amounts of compounds of formula (I) (e.g., compound 1001) are added to the plate for capture by the plate-bound recombinant Trim7 protein. Recombinant human RACO1 and / or MSK1 protein is added to the plate with or without compounds of formula (I) (e.g., compound 1001). The binding is then detected using anti- RACO1 antibody and / or anti- and / or MSK1 antibody in combination with a SULFO-TAG conjugated secondary antibody. It is expected that Trim7 will exhibit binding to RACO1 and / or MSK1 protein in the absence of compounds of formula (I) (See FIG.1A and FIG.1B). It is anticipated that Trim7 will exhibit reduced binding to RACO1 and / or MSK1 protein when the detection is performed in the presence compounds of formula (I). These results will demonstrate, inter alia, that compounds of formula (I) disrupt the binding of recombinant human Trim7 protein to RACO1 and / or MSK1 protein. Accordingly, the compounds of formula (I) are inhibitors of Trim7, which are useful in the methods disclosed herein. Example 6: IC50 data of compounds of the disclosure This Example provides data showing IC50 values of compounds of the disclosure from a TRIM7 fluorescence polarization (FP) binding assay. A TRIM7 fluorescence polarization (FP) binding assay was performed on compounds of the disclosure. The assay was performed using the far C-terminal 9 amino acids (GATLEALFQ (SEQ ID NO: 1) of a fluorescently labeled viral peptide (CVB3) previously shown to interact with the same TRIM7-PrySpry(324-511) domain (Ru, Y. Proc. Natl. Acad. Sci. U.S.A., 2022, 119(30): e2203218119), which was incubated for 22 hours with His-TRIM7-PrySpry(324-511). An unlabeled version of the same peptide, a shorter version of that peptide (LFQ only), or the small molecule inhibitors (SMIs) were added to compete with the binding of the fluorescently labeled peptide to the same docking pocket. The loss of fluorescent signal as the labeled peptide is competed off was quantified. The results are shown in the table below, where the IC50is indicated as follows: +++ = IC50< 15 µM ++ = 15 µM < IC50< 100 µM + = IC50> 100 µM N / A = Compound not yet tested Example 7: Covalent Trim7 inhibitors of the disclosure This Example provides data showing relative IC50 values of compounds of the disclosure from a TRIM7 fluorescence polarization (FP) binding assay calculated at 4 hours and at 22 hours. Although not wishing to be bound by any particular theory, the improved IC50 determined at 22 hours compared to the IC50 determined for compounds 1013 and 1012 demonstrates that over time, the compounds are covalently binding to Trim7, thereby improving their ability to inhibit the gene. For each compound tested, the IC50values shown in the table below at time 22 hr are relative to the IC50value at 4 h (with the relative IC50value at 4 h being 1). Example 8: IC50 data of compounds of the disclosure A TRIM7 fluorescence polarization (FP) binding assay was performed on compounds of the disclosure. The assay was performed using the far C-terminal 9 amino acids (GATLEALFQ (SEQ ID NO: 1)) of a fluorescently labeled viral peptide (CVB3) previously shown to interact with the same TRIM7-PrySpry(324-511) domain, which was incubated for 1.5 hours, 4 hours, or 22 hours with His-TRIM7-PrySpry(324-511). An unlabeled version of the same peptide, a shorter version of that peptide (LFQ only), or the small molecule inhibitors (SMIs) were added to compete with the binding of the fluorescently labeled peptide to the same docking pocket. The loss of fluorescent signal as the labeled peptide is competed off was quantified. The results are shown in the table below, where the IC50 is indicated as follows: +++ = IC50< 15 µM ++ = 15 µM < IC50< 100 µM + = IC50> 100 µM N / A = Compound not yet tested Example 9: TRIM7 interaction with SMIs of the disclosure TRIM7 is most described in viral biology, where it ubiquitinates viral proteins (e.g., CVB3_2BC, EV71, and SARS- CoV2) and targets them for degradation (FIG.9A). The crystal structure of the c-term PrySpry domain of TRIM7 was recently solved, identifying the key pocket where viral binding could occur (FIG.9B). The crystal structure of TRIM7 with viral peptide was solved and identified a key cysteine in the binding pocket that could be exploited for covalent binding (FIG.9C). Importantly, the c-term amino acids of viral CVB3_2C were shown to specifically interact in this pocket, and this amino acid motif is conserved with the native proteins GN1 and RACO-1. These structural learnings partially informed the small molecule inhibition of TRIM7. Recombinant proteins were generated to facilitate small molecule inhibitor (SMI) development and to verify binding / functional activity. TRIM7 interactions with RACO-1, STING, MAVS, and CVB3_2C (WT but not mutant) were confirmed (FIG.10). Using these findings, various compounds of the disclosure were screened through a series of binding / activity assays, and prioritized for further chemical modification (FIG.11). Table 1 provides binding data for several compounds of the disclosure to the PrySpry domain. Binding was assessed qualitatively, with a score of *, **, ***, or **** based on whether the correct SMI mass was detected following incubation with TRIM7_PrySpry (Full Scan), and whether an interaction was confirmed at the intended C501 in the binding pocket (peptide mapping). Legend: Scores of * or ** indicate some binding was detected however assay requires further optimization. Scores of *** or **** indicate high confidence binding. ND indicates that the compound has not been tested. Table 1. Binding data to the PrySpry domain for compounds of the disclosure FIGS. 12A-12B are cell-based activity assays demonstrating that TRIM7 expression in cells results in target degradation / stabilization. FIG.12A demonstrates that the over expression of TRIM7 (+T7) in 293T cell lines expressing CVB3, MAVS, or STING results in their degradation, consistent with previous studies. FIG.12B demonstrates that RACO-1 over-expressed on its own, resulting in self-ubiquitination and degradation. When TRIM7 is co-expressed with RACO1, RACO1 is stabilized. TRIM7 SMIs, such as compound 1028, have varying activities in blocking TRIM7 stabilization of RACO1, resulting in its degradation. Example 10: IC50values of compounds of the disclosure This Example provides data showing IC50 values compound 1028 of the disclosure from a TRIM7 fluorescence polarization (FP) binding assay. A TRIM7 fluorescence polarization (FP) binding assay was performed on compound 1028. The assay was performed using the far C-terminal 9 amino acids (GATLEALFQ (SEQ ID NO: 1)) of a fluorescently labeled viral peptide (CVB3) previously shown to interact with the same TRIM7-PrySpry(324-511) domain (Ru, Y. et al., Proc. Natl. Acad. Sci. U.S.A., 2022, 119(3): e2203218119), which was incubated for 30 minutes with His-TRIM7-PrySpry(324-511). An unlabeled version of the same peptide, a shorter version of that peptide (LFQ only), or the small molecule inhibitors (SMIs) were added to compete with the binding of the fluorescently labeled peptide to the same docking pocket for 1.5 hours. The loss of fluorescent signal as the labeled peptide is competed off was quantified. The results are shown in the table below, where the IC50is indicated as follows: Key: +++ = IC50 < 15 µM ++ = 15 µM < IC50 < 100 µM + = IC50 > 100 µM Example 11: In vivo anti-tumor activity of a compound of formula (I) in Combination with a kras Inhibitor The efficacy of a compound of formula (I) is evaluated in combination with a kras inhibitor. Briefly, BALB / C mice are inoculated with 500,000 murine colon carcinoma CT26 cells on the rear flank. When average tumor volume reached 80-100 mm3(indicating day 0), mice, the mice are randomly distributed in four following treatment groups. The groups of mice are administered (1) vehicle only control, (2) a compound of formula (I) alone, (3) kras inhibitor alone, or (4) a combination of a compound of formula (I) and a kras inhibitor. The administration is performed on days on days 0, 3, 6, 9, 12, and 15. Tumors are measured with electronic calipers on every day and plotted using the GraphPad Prism software. The tumor growth for each treatment group is assessed by plotting tumor growth curves of

[0014] individual mice, average tumor growth curves for treatment groups, average tumor sizes on an illustrative day, and / or Kaplan-Meier plots. The results are expected to demonstrate, inter alia, that the combination of a compound of formula (I) and a kras inhibitor has greater anti-tumor activity compared to either single treatment. Example 12: In vivo anti-tumor activity of a compound of formula (I) in Combination with a braf Inhibitor The efficacy of a compound of formula (I) is evaluated in combination with a braf inhibitor. Briefly, BALB / C mice are inoculated with 500,000 murine colon carcinoma CT26 cells on the rear flank. When average tumor volume reached 80-100 mm3(indicating day 0), mice, the mice are randomly distributed in four following treatment groups. The groups of mice are administered (1) vehicle only control, (2) a compound of formula (I) alone, (3) braf inhibitor alone, or (4) a combination of a compound of formula (I) and a braf inhibitor. The administration is performed on days on days 0, 3, 6, 9, 12, and 15. Tumors are measured with electronic calipers on every day and plotted using the GraphPad Prism software. The tumor growth for each treatment group is assessed by plotting tumor growth curves of individual mice, average tumor growth curves for treatment groups, average tumor sizes on an illustrative day, and / or Kaplan-Meier plots. The results are expected to demonstrate, inter alia, that the combination of a compound of formula (I) and a braf inhibitor has greater anti-tumor activity compared to either single treatment. Example 13: In vivo anti-tumor activity of a compound of formula (I) in Combination with a MEK Inhibitor The efficacy of a compound of formula (I) is evaluated in combination with a MEK inhibitor. Briefly, BALB / C mice are inoculated with 500,000 murine colon carcinoma CT26 cells on the rear flank. When average tumor volume reached 80-100 mm3(indicating day 0), mice, the mice are randomly distributed in four following treatment groups. The groups of mice are administered (1) vehicle only control, (2) a compound of formula (I) alone, (3) MEK inhibitor alone, or (4) a combination of a compound of formula (I) and a MEK inhibitor. The administration is performed on days on days 0, 3, 6, 9, 12, and 15. Tumors are measured with electronic calipers on every day and plotted using the GraphPad Prism software. The tumor growth for each treatment group is assessed by plotting tumor growth curves of individual mice, average tumor growth curves for treatment groups, average tumor sizes on an illustrative day, and / or Kaplan-Meier plots. The results are expected to demonstrate, inter alia, that the combination of a compound of formula (I) and a MEK inhibitor has greater anti-tumor activity compared to either single treatment. Example 14: IC50data of compounds of the disclosure This Example provides data showing IC50values of compounds of the disclosure from a TRIM7 fluorescence polarization (FP) binding assay. A TRIM7 fluorescence polarization (FP) binding assay was performed on compounds of the disclosure. The assay was performed using the far C-terminal 9 amino acids (GATLEALFQ (SEQ ID NO: 1)) of a fluorescently labeled viral peptide (CVB3) previously shown to interact with the same TRIM7-PrySpry(324-511) domain (Ru, Y. et al., Proc. Natl. Acad. Sci. U.S.A., 2022, 119(3): e2203218119), which was incubated for 30 minutes, 1.5 hours, 4 hours, or 22 hours with His-TRIM7-PrySpry(324-511). An unlabeled version of the same peptide, a shorter version of that peptide (LFQ only), or the small molecule inhibitors (SMIs) were added to compete with the binding of the fluorescently labeled peptide to the same docking pocket. The loss of fluorescent signal as the labeled peptide is competed off was quantified. The results are shown in the table below, where the IC50 is indicated as follows: Key: +++ = IC50 < 15 µM ++ = 15 µM < IC50 < 100 µM + = IC50 > 100 µM N / A = Compound not yet tested Example 15 Synthesis of 5-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1010): Preparation of 2-(dibenzylcarbamoyl)-5-nitrobenzoic acid and 2-(dibenzylcarbamoyl)-4-nitrobenzoic acid (Int- 1a) (Step 1): 5-nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and bis(benzylamine) (2.0 g, 10.4 mmol, 1.0 eq.) were taken in THF (25 ml) and the solution was stirred at room temperature for 18 hrs. The solution was concentrated to afford a 1:1 mixture of the desired products as a clear oil (4.0 g, 100% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 8.63 (d, J=2.4 Hz, 1H), 8.43 – 8.40 (m, 1H), 8.27 (d, J=2.4 Hz, 1H), 8.17 (d, J=3.2 Hz, 1H), 8.04 (J=2.4 Hz, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.35 – 7.05 (m, 20H), 4.23 (br s, 2H),4.18 (br s, 2H). LCMS EI-MS m / z: = 391.0[M+H]+. Preparation of 5-amino-2-(dibenzylcarbamoyl)benzoic acid (Int-1b) (Step 2): The mixture of 2- (dibenzylcarbamoyl)-5-nitrobenzoic acid and 2-(dibenzylcarbamoyl)-4-nitrobenzoic acid (Int-1a) (1.50 g, 3.84 mmol) was taken in ethanol (38 ml) and Pd / C (0.3 g, 20 wt%) was added to it. The suspension was kept under a hydrogen balloon for 24 hrs. The insoluble catalysts were removed by filtration through celite, and the filtrate was concentrated. The residue was purified on preparative reverse phase HPLC using water / acetonitrile with 0.05% TFA to give two products. The faster eluting compound (0.8 g, 40% yield) was assigned the structure of the title compound based on 2D NMR analysis.1H NMR (400 MHz, DMSO-d6) δ ppm 7.65 – 7.25 (m, 8H), 7.20 – 7.15 (m, 3H), 7.10 – 7.05 (m, 1H), 6.73 (d, J=8.4 Hz, 1H), 4.54 (s, 2H), 4.21 (s, 2H), 4.00 – 3.00 (br, 2H). LCMS EI-MS m / z: = 361.2[M+H]+. Preparation of 5-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1010) (Step 3): 5-amino-2- [bis(benzyl)carbamoyl]benzoic acid—trifluoroacetic acid (1 / 1) (100 mg, 0.20 mmol) was taken in 1N sodium hydroxide solution (2.0 ml) and acryloyl chloride (0.05 ml, 0.60 mmol, 3.0 eq.) was added. The solution was stirred for 3 hrs at room temperature. The reaction was quenched by adding 1N hydrochloric acid, which led to precipitation of a white solid. The solids were collected by filtration and then purified on preparative reverse phase HPLC using water / acetonitrile with 0.05% TFA to afford the title compound as a white powder. (46 mg, 55% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 8.37 (d, J=2.0 Hz, 1H), 7.95 (dd, J=8.4 Hz, 2.0 Hz, 1H), 7.50 – 7.10 (m, 11 Hz), 6.50 – 6.30 (m, 2H), 5.80 (dd, J=8.8 Hz, 3.2 Hz, 1H), 4.70 (br s, 2H), 4.26 (s, 2H). LCMS EI-MS m / z: = 415.1[M+H]+. Example 16 Synthesis of 4-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1011): 4-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1011) was synthesized from 4-amino-2- (dibenzylcarbamoyl)benzoic acid (Int-1c)(80 mg, 0.02 mmol) and acryloyl chloride (0.04 ml, 0.05 mmol) following the procedure described in Step 3 for the synthesis of compound 1010 to afford the title compound (20 mg, 21% yield).1H NMR (400 MHz, METHANOL–d4) δ = 8.07 (d, J = 8.6 Hz, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.75 (dd, J = 2.1, 8.6 Hz, 1H), 7.39 – 7.22 (m, 8H), 7.14 (d, J = 6.6 Hz, 2H), 6.43 (d, J = 2.4 Hz, 2H), 5.82 (dd, J = 4.7, 7.1 Hz, 1H), 4.23 (br s, 2H). LCMS EI-MS m / z: = 415.1[M+H]+. Example 17 Synthesis of 5-acrylamido-2-(diisobutylcarbamoyl)benzoic acid (Compound 1012): 5-acrylamido-2-(diisobutylcarbamoyl)benzoic acid (Compound 1012) was synthesized from 5- nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and diisobutylamine (1.3 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (15 mg, 28% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 8.33 (d, J=2.0 Hz, 1H), 7.98 (dd, J=8.2, 2.0 Hz, 1H), 7.27 (d, J=8.0 Hz, 2H), 6.50 – 6.40 (m, 4H), 5.81 (dd, J=9.2, 3.2 Hz, 2H), 3.37 (d, J=7.8 Hz, 2H), 2.98 (d ,J=7.8 Hz, 2H), 2.25 – 2.15 (m, 1H), 1.85 – 1.70 (m, 1H), 1.02 (d, J=6.4 Hz, 6H), 0.77 (d, J=6.4 Hz, 6H). LCMS EI-MS m / z: = 347.1[M+H]+. Example 18 Synthesis of 4-acrylamido-2-(diisobutylcarbamoyl)benzoic acid (Compound 1013): 4-acrylamido-2-(diisobutylcarbamoyl)benzoic acid (Compound 1013) was synthesized from 5- nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and diisobutylamine (1.3 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1011 to afford the title compound (13 mg, 20% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 8.03 (d, J=8.4 Hz, 1H), 7.80 – 7.40 (m, 2H), 6.50 – 6.30 (m, 2H), 5.81 (dd, J=8.4, 3.2 Hz, 1H), 3.75 (d, J=7.6 Hz, 2H), 3.00 (br, s, 2H), 2.25 – 2.20 (m, 1H), 1.95 – 1.85 (m, 1H), 1.03 (d, J=6.4 Hz, 6H), 0.79 (d, J=6.4 Hz, 6H). LCMS EI-MS m / z: = 347.1[M+H]+Example 19 Synthesis of 4-bromo-2-(diisobutylcarbamoyl)benzoic acid (Compound 1014): 4-bromo-2-(diisobutylcarbamoyl)benzoic acid (Compound 1014) was synthesized from 5-bromoisobenzofuran- 1,3-dione (1.6 g, 8.3 mmol) and diisobutylamine (1.1 g, 8.3 mmol, 1.0 eq.) following the procedure described in Step 1 for the synthesis of compound 1011 to afford the title compound (900 mg, 47% yield).1H NMR (400 MHz, CDCl3) δ ppm 8.11 (s,1H), 7.62 (d, J=8.2 Hz, 1H), 7.55 (d, J=8.2 Hz, 1H), 3.75 (d, J=7.6 Hz, 2H), 3.00 (br, s, 2H), 2.25 – 2.20 (m, 1H), 1.95 – 1.85 (m, 1H), 1.03 (d, J=6.4 Hz, 6H), 0.79 (d, J=6.4 Hz, 6H). LCMS EI-MS m / z: = 432.1, 434.1[M+H]+. Example 20 Synthesis of 5-amino-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1015): 5-amino-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1015) was synthesized from 5-nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and N-(cyclohexylmethyl)-2-methoxyethan-1-amine (1.8 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (160 mg, 56% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.80 (d, J = 8.6 Hz, 1H), 6.67 (dd, J = 2.3, 8.6 Hz, 1H), 6.46 (dd, J = 2.3, 10.7 Hz, 1H), 3.75 – 3.62 (m, 2H), 3.57 – 3.32 (m, 4H), 3.29 – 3.17 (m, 2H), 3.11 – 2.99 (m, 1H), 2.99 – 2.83 (m, 1H), 1.99 – 1.80 (m, 2H), 1.76 (br d, J = 12.4 Hz, 1H), 1.71 – 1.52 (m, 4H), 1.38 – 1.10 (m, 3H), 1.08 – 1.00 (m, 1H), 0.69 (br t, J = 10.6 Hz, 1H). LCMS EI-MS m / z: = 335.2[M+H]+. Example 21 Synthesis of 4-amino-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1016): 4-amino-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1016) was synthesized from 5-nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and N-(cyclohexylmethyl)-2-methoxyethan-1-amine (1.8 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1011 to afford the title compound (150 mg, 29% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.50 (s, 1H), 7.15 – 7.01 (m, 2H), 3.69 – 3.62 (m, 2H), 3.38 – 3.36 (m, 3H), 3.29 – 3.15 (m, 2H), 1.89 – 1.73 (m, 3H), 1.71 – 1.56 (m, 4H), 1.35 – 1.14 (m, 3H), 1.11 – 0.97 (m, 2H), 0.72 – 0.57 (m, 1H). LCMS EI-MS m / z: = 335.2[M+H]+. Example 22 Synthesis of 2-(diisobutylcarbamoyl)-5-ethynylbenzoic acid (Compound 1017):

[0015] Int-2a was prepared as described in Compound 1014. Int-2b was prepared from Int-2a using thionyl chloride in methanol. Int-2c was prepared from Int-2b using TMS-acetylene, Pd(PPh3)4, Copper(I) iodide in triethylamine. Compound 1017 was prepared from Int-2c using aqueous sodium hydroxide to afford the title compound (15 mg, 9% yield).1H NMR (400 MHz, METHANOL–d4) δ = 8.10 (s, 1H), 7.71 (dd, J = 1.4, 7.9 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 3.70 (s, 1H), 3.43 – 3.32 (m, 2H), 2.95 (br s, 2H), 2.19 (quind, J = 6.8, 13.7 Hz, 1H), 1.85 (quind, J = 6.9, 13.7 Hz, 1H), 1.02 (d, J = 6.6 Hz, 6H), 0.77 (d, J = 6.6 Hz, 6H). LCMS EI-MS m / z: = 302.1[M+H]+. Example 23 Synthesis of 4-amino-2-(dibenzylcarbamoyl)benzoic acid (Compound 1018): 4-amino-2-(dibenzylcarbamoyl)benzoic acid (Compound 1018) was synthesized from 5-nitroisobenzofuran-1,3- dione (2.0 g, 10.4 mmol) and N,N-dibenzylamine (2.2 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-2 for the synthesis of compound 1010 to afford the title compound (100 mg, 30% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 7.55 – 7.25 (m, 8H), 7.20 – 7.15 (3H), 7.10 – 7.00 (m, 1H), 6.73 (d, J=8.4 Hz, 1H), 4.54 (br 2H), 4.21 (s, 2H), 4.00 – 3.70 (br 1H). LCMS EI-MS m / z: = 361.1[M+H]+. Example 24 Synthesis of 5-amino-2-(dibenzylcarbamoyl)benzoic acid (Compound 1019): 5-amino-2-(dibenzylcarbamoyl)benzoic acid (Compound 1019) was synthesized from 5-nitroisobenzofuran-1,3- dione (2.0 g, 10.4 mmol) and N,N-dibenzylamine (2.2 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1011 to afford the title compound (150 mg).1H NMR (400 MHz, DMSO-d6) δ ppm 7.75 – 7.50 (m, 8H), 7.25 – 7.20 (3H), 7.10 – 7.00 (m, 1H), 6.52 (d, J=8.0 Hz, 1H), 4.50 (br 2H), 3.95 (s, 2H), 4.00 – 3.70 (br 1H). LCMS EI-MS m / z: = 361.1[M+H]+. Example 25 Synthesis of 5-acrylamido-2-((4-chlorobenzyl)carbamoyl)benzoic acid (Compound 1020): 5-acrylamido-2-((4-chlorobenzyl)carbamoyl)benzoic acid (Compound 1020) was synthesized from 5- nitroisobenzofuran-1,3-dione (0.4 g, 2.1 mmol) and 4-chlorobenzylamine (0.3 g, 2.1 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (12 mg). LCMS EI- MS m / z: = 359.1[M+H]+. Example 26 Synthesis of 5-acrylamido-2-(benzyl(4-methylbenzyl)carbamoyl)benzoic acid (Compound 1021):

[0016] 5-acrylamido-2-(benzyl(4-methylbenzyl)carbamoyl)benzoic acid (Compound 1021) was synthesized from 5- nitroisobenzofuran-1,3-dione (2.0 g, 10.4 mmol) and N-benzyl-1-(p-tolyl)methanamine (2.2 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (18 mg).1H NMR (400 MHz, METHANOL–d4) δ = 8.37 (s, 1H), 7.95 (t, J = 7.0 Hz, 1H), 7.41 – 7.21 (m, 6H), 7.17 – 7.08 (m, 3H), 7.01 (d, J = 8.0 Hz, 1H), 6.47 – 6.35 (m, 2H), 5.80 (dd, J = 2.2, 8.8 Hz, 1H), 4.22 (br d, J = 12.3 Hz, 2H), 2.32 (d, J = 11.1 Hz, 3H). LCMS EI-MS m / z: = 429.1[M+H]+. Example 27 Synthesis of 5-acrylamido-2-(benzyl(4-methylbenzyl)carbamoyl)benzoic acid (Compound 1023): 5-acrylamido-2-(benzyl(4-methylbenzyl)carbamoyl)benzoic acid (Compound 1023) was synthesized from 5- nitroisobenzofuran-1,3-dione (320 mg, 1.6 mmol) and bis[(p-chlorophenyl)methyl]amine (440 g, 1.6 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (10 mg, 19% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 13.45 (br s, 1H), 10.44 (s, 1H), 8.28 (d, J=2.4 Hz, 1H), 7.90 (d, J=2.4 Hz, 1H), 7.51 – 7.35 (m, 7H), 7.25 – 7.15 (m, 2H), 6.45 – 6.40 (m, 1H), 6.37 – 6.30 (m, 1H), 5.80 – 5.75 (m, 1H), 4.60 (br s, 2H), 4.19 (s, 2H). LCMS EI-MS m / z: = 484.1[M+H]+. Example 28 Synthesis of 5-acrylamido-2-(bis(3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)benzoic acid (Compound 1024):

[0017] 5-acrylamido-2-(bis(3-fluoro-4-(trifluoromethyl)benzyl)carbamoyl)benzoic acid (Compound 1024) was synthesized from 5-nitroisobenzofuran-1,3-dione (170 mg, 0.9 mmol) and bis(3-fluoro-4-(trifluoromethyl)benzyl)amine (320 g, 0.9 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (10 mg, 17% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 13.60 (br s, 1H), 10.46 (s, 1H), 8.31 (d, J=2.0 Hz, 1H), 7.94 – 7.92 (m, 1H), 7.80 – 7.20 (m, 7H), 6.51 – 6.43 (m, 1H), 6.34 - 6.26 (m, 1 H), 5.85 – 5.80 (m, 1H), 4.75 (br s, 2H), 4.42 (s, 2H). LCMS EI-MS m / z: = 587.0[M+H]+. Example 29 Synthesis of 5-acrylamido-2-(bis(4-methoxybenzyl)carbamoyl)benzoic acid (Compound 1025): 5-acrylamido-2-(bis(4-methoxybenzyl)carbamoyl)benzoic acid (Compound 1025) was synthesized from 5- nitroisobenzofuran-1,3-dione (350 mg, 1.8 mmol) and bis(4-methoxybenzyl)amine (466 mg, 1.8 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (30 mg, 11% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 13.45 (br s, 1H), 10.44 (s, 1H), 8.27 (s, 1H), 7.91 (d, J=2.0 Hz, 1H), 7.40 – 6.90 (m, 9H), 6.50 – 6.30 (m, 2H), 5.82 – 5.80 (m, 1H), 4.50 (br s, 2H), 4.07 (s, 2H), 3.75 (s, 3H), 3.74 (s, 3H). LCMS EI-MS m / z: = 475.2[M+H]+. Example 30 Synthesis of 5-acrylamido-2-(benzyl(4-fluorobenzyl)carbamoyl)benzoic acid (Compound 1027):

[0018] 5-acrylamido-2-(benzyl(4-fluorobenzyl)carbamoyl)benzoic acid (Compound 1027) was synthesized from 5- nitroisobenzofuran-1,3-dione (180 mg, 0.9 mmol) and (benzyl)[(p-fluorophenyl)methyl]amine (200 mg, 0.9 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (40 mg, 9% yield).1H NMR (400 MHz, DMSO-d6)δ ppm 13.44 (br s, 1H), 10.44 (d, J=2.1 Hz, 1H), 8.28 (s, 1H), 7.88 - 7.96 (m, 1H), 7.25 - 7.43 (m, 6H), 7.09 - 7.22 (m, 4H), 6.40 (dd, J=10.1 , 1.8 Hz, 1H) 6.25 - 6.34 (m, 1H) 5.80 (br d, J=10.1 Hz, 1H), 4.52 (s, 2H), 4.19 (s, 2H). LCMS EI-MS m / z: = 433.1[M+H]+. Example 31 Synthesis of 5-acrylamido-2-(benzyl((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)benzoic acid (Compound 1028): 5-acrylamido-2-(benzyl((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)benzoic acid (Compound 1028) was synthesized from 5-nitroisobenzofuran-1,3-dione (1.5 g, 7.8 mmol) and benzyl[(oxan-4-yl)methyl]amine (1.6 g, 7.8 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (10 mg, 15% yield).1H NMR (400 MHz, METHANOL–d4) δ ppm 8.41 – 8.37 (m, 2H), 7.91 (dd, J = 2.1, 8.4 Hz, 1H), 7.52 (d, J = 7.3 Hz, 2H), 7.41 – 7.27 (m, 9H), 7.23 (d, J = 7.1 Hz, 3H), 6.49 – 6.37 (m, 4H), 5.82 (dd, J = 3.1, 8.5 Hz, 2H), 4.43 (s, 3H), 3.95 (br dd, J = 3.0, 11.4 Hz, 3H), 3.51 – 3.35 (m, 5H), 3.31 – 3.12 (m, 3H), 2.68 (s, 1H), 1.78 (br d, J = 11.1 Hz, 4H). LCMS EI-MS m / z: = 423.1[M+H]+. Example 32 Synthesis of 5-acrylamido-2-((3-fluoro-4-(trifluoromethyl)benzyl)((tetrahydro-2H-pyran-4- yl)methyl)carbamoyl)benzoic acid (Compound 1029): 5-acrylamido-2-((3-fluoro-4-(trifluoromethyl)benzyl)((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)benzoic acid (Compound 1029) was synthesized from 5-nitroisobenzofuran-1,3-dione (670 mg, 3.4 mmol) and {[3-fluoro-4- (trifluoromethyl)phenyl]methyl}[(oxan-4-yl)methyl]amine (1.0 g, 3.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (35 mg, 17% yield).1H NMR (400 MHz, DMSO-d6) δ ppm 13.4 (br s, 1H), 10.43 (d, J=28 Hz, 1H), 8.31 (d, J=2.0 Hz, 1H), 8.10 – 7.20 (m, 5H), 6.50 – 6.20 (m, 2H), 5.80 - 5.75 (m, 1H), 4.82 (br s, 1H), 4.45 (s, 1H), 3.30 – 3.00 (m, 4H), 2.10 – 1.80 (m, 1H), 1.80 – 1.70 (m, 1H), 1.50 – 1.40 (m, 1H), 1.20 – 1.10 (m, 2H), 0.90 – 0.80 (m, 2H). LCMS EI-MS m / z: = 509.1[M+H]+. Example 33 Synthesis of 5-acrylamido-2-((4-methoxybenzyl)((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)benzoic acid (Compound 1030): 5-acrylamido-2-((4-methoxybenzyl)((tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)benzoic acid (Compound 1030) was synthesized from 5-nitroisobenzofuran-1,3-dione (1.5 g, 7.8 mmol) and [(p- methoxyphenyl)methyl][(tetrahydro-2H-pyran-4-yl)methyl]amine (1.8 g, 7.8 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of Compound 1010 to afford the title compound (35 mg). LCMS EI-MS m / z: = 453.1[M+H]+. Example 34 Synthesis of 5-acrylamido-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1031): 5-acrylamido-2-((cyclohexylmethyl)(2-methoxyethyl)carbamoyl)benzoic acid (Compound 1031) was synthesized from 5-nitroisobenzofuran-1,3-dione (1.5 g, 7.8 mmol) and (cyclohexylmethyl)(2-methoxyethyl)amine (1.3 g, 7.8 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (35 mg).1H NMR (400 MHz, METHANOL–d4) δ = 8.33 (dd, J = 1.6, 8.3 Hz, 1H), 7.97 (t, J = 6.7 Hz, 1H), 7.27 (t, J = 8.9 Hz, 1H), 6.49 – 6.36 (m, 2H), 5.81(dd, J = 1.9, 9.1 Hz, 1H), 3.77 – 3.60 (m, 2H), 3.44 – 3.36 (m, 3H), 3.35 – 3.29 (m, 3H), 3.23 (s, 1H), 3.14 – 2.92 (m, 1H), 1.96 – 1.82 (m, 1H), 1.81 – 1.56 (m, 5H), 1.34 – 1.14 (m, 2H), 1.12 – 0.98 (m, 1H), 0.73 – 0.58 (m, 1H). LCMS EI-MS m / z: = 389.1[M+H]+. Example 35 Synthesis of 5-acrylamido-2-(benzyl(4-methoxybenzyl)carbamoyl)benzoic acid (Compound 1032): 5-acrylamido-2-(benzyl(4-methoxybenzyl)carbamoyl)benzoic acid (Compound 1032) was synthesized from 5- nitroisobenzofuran-1,3-dione (1.5 g, 7.8 mmol) and N-benzyl-1-(4-methoxyphenyl)methanamine (1.8 g, 7.8 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (4 mg, 6% yield).1H NMR (400 MHz, METHANOL–d4) δ = 8.43 – 8.30 (m, 1H), 8.02 – 7.85 (m, 1H), 7.44 – 7.20 (m, 7H), 7.18 – 7.08 (m, 1H), 7.07 – 6.96 (m, 1H), 6.92 – 6.75 (m, 2H), 6.49 – 6.32 (m, 2H), 5.85 – 5.70 (m, 1H), 4.28 – 4.12 (m, 3H), 3.86 – 3.66 (m, 4H), 3.34 (s, 4H). LCMS EI-MS m / z: = 445.1[M+H]+. Example 36 Synthesis of 5-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1033): 5-acrylamido-2-(dibenzylcarbamoyl)benzoic acid (Compound 1033) was synthesized from 5-nitroisobenzofuran- 1,3-dione (2.0 g, 10.4 mmol) and dibenzylamine (2.0 g, 10.4 mmol, 1.0 eq.) following the procedure described in Steps 1-3 for the synthesis of compound 1010 to afford the title compound (6 mg).1H NMR (400 MHz, METHANOL– d4) δ = 8.30 (d, J = 2.1 Hz, 1H), 7.86 (dd, J = 2.1, 8.3 Hz, 1H), 7.38 – 7.23 (m, 9H), 7.12 (d, J = 6.8 Hz, 2H), 4.84 – 4.57 (m, 2H), 4.24 (s, 2H), 3.37 – 3.32 (m, 1H), 2.40 (q, J = 7.6 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H). LCMS EI-MS m / z: = 429.1[M+H]+. Example 37 Synthesis of 2-(5-acrylamido-2-(benzyl(methyl)carbamoyl)phenyl)acetic acid (Compound 1034): Synthesis of ethyl 2-(2-(benzyl(methyl)carbamoyl)-5-bromophenyl)acetate (Int-3b): A solution of 4-bromo-2-(2- ethoxy-2-oxoethyl)benzoic acid (1.8 g, 6.1 mmol) in dichloromethane (30 ml) was reacted with oxalyl chloride (0.7 ml, 8.0 mmol, 1.3 eq.) in the presence of DMF (0.2 ml). After 3 hrs, the solution was concentrated to give the corresponding acid chloride (1.8 g). A solution of this acid chloride (0.75 g, 2.6 mmol) was reacted with N- methylbenzyamine (0.36 ml, 2.8 mmol, 1.1 eq.) and diisopropylethylamine (0.58 ml, 3.3 mmol, 1.3 eq) to afford the title compound (910 mg, 95% yield). LCMS EI-MS m / z: = 391.1, 393.1[M+H]+. Synthesis of 2-(5-amino-2-(benzyl(methyl)carbamoyl)phenyl)acetic acid (Int-3c): A solution of ethyl 2-(2- (benzyl(methyl)carbamoyl)-5-bromophenyl)acetate (910 mg, 2.3 mmol) and lithium hydroxide (223 mg, 9.3 mmol, 4.0 eq.) in THF (2 ml) and water (4 ml) was stirred for 6 hrs. It was then acidified by adding 1N HCl solution and extracted into dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the corresponding acid (750 mg, 89% yield). A solution of this acid (300 mg, 0.83 mmol), copper oxide (60 mg, 0.4 mmol, 0.5 eq.) and ammonium hydroxide (0.07 ml, 1.7 mmol, 2.0 eq.) was taken in NMP (6 ml) and heated to 80 C for 16 hrs. After cooling the solution was added to ethyl acetate and washed with water. The organic layer was dried over magnesium sulfate, filtered, and then concentrated. The residue was purified on Combiflash using dichloromethane / methanol gradient to afford the title product (50 mg, 25% yield). LCMS EI-MS m / z: = 299.0[M+H]+. Synthesis of 2-(5-acrylamido-2-(benzyl(methyl)carbamoyl)phenyl)acetic acid (Compound 1034): 2-(5-amino-2- (benzyl(methyl)carbamoyl)phenyl)acetic acid (Int-3c) (40 mg, 0.17 mmol) was taken in 2 N NaOH solution (1 ml) and acryloyl chloride (0.05 ml, 0.4 mmol, 2.5 eq.) was added. After stirring for 3 hrs, the solution was quenched by adding 1 N HCl solution. It was then extracted with dichloromethane 3 times. The combined organic layers were dried over magnesium sulfate, filtered, and then concentrated. The residue was purified on Combiflash using dichloromethane / methanol gradient to afford the title product as a white powder (10 mg, 17% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.75 – 7.60 (m, 2H), 7.40 – 7.26 (m, 5H), 7.20 (br d, J = 7.5 Hz, 1H), 6.47 – 6.33 (m, 2H), 5.81 – 5.75 (m, 1H), 4.83 – 4.69 (m, 2H), 4.45 (br s, 1H), 3.72 (br s, 2H), 3.01 (s, 1H), 2.83 (s, 2H), 1.94 (s, 1H). LCMS EI-MS m / z: = 353.1[M+H]+. Example 38 Synthesis of methyl 4-(benzyl(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxylate (Compound 1035):

[0019] Synthesis of methyl 2-(4-(benzyl(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetate (Int-3d): A solution of methyl 2-(2-(benzyl(methyl)carbamoyl)-5-bromophenyl)acetate (Int-3b) (140 mg, 0.37 mmol), (2- (trifluoromethyl)phenyl)boronic acid (78 mg, 0.41 mmol, 1.1 eq.) and sodium carbonate (79 mg, 0.75 mmol, 2.0 eq.) in 1,4-dioxane (2 ml) and water (2 ml) was degassed with nitrogen. 1,1'-Bis(diphenylphosphino)ferrocene palladium(II)dichloride dichloromethane complex (15 mg, 0.02 mmol, 0.05 eq.) was added and the solution was degassed with nitrogen followed by heated to 80 C for the next 16 hrs. After cooling, the solution was filtered through celite, and the filtrate was concentrated. The residue was purified on Combiflash using dichloromethane / methanol gradient to afford the title product (56 mg, 33% yield). LCMS EI-MS m / z: = 442.1[M+H]+. Synthesis of 2-(4-(benzyl(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1035): A solution of methyl 4-(benzyl(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-carboxylate (56 mg, 0.013 mmol) and lithium hydroxide (12 mg, 0.51 mmol, 4.0 eq) in THF (2 mL) and water (2 ml) was heated to 50 °C for 2 hrs. After cooling, the solution was acidified using aqueous HCl and then extracted with dichloromethane. The organic layer was dried over magnesium sulfate, filtered, and then concentrated. The residue was purified on Combiflash using dichloromethane / methanol gradient to afford the title product as a white powder (28 mg, 56% yield). LCMS EI-MS m / z: = 428.1[M+H]+. Example 39 Synthesis of 2-(5-acrylamido-2-(dibenzylcarbamoyl)phenyl)acetic acid (Compound 1036): 2-(5-acrylamido-2-(dibenzylcarbamoyl)phenyl)acetic acid (Compound 1036) was synthesized from 4-bromo-2- (2-ethoxy-2-oxoethyl)benzoic acid (1.7 g, 5.8 mmol) and dibenzylamine (1.1 g, 5.4 mmol) following the procedure described in Steps 7-9 for the synthesis of compound 1034 to afford the title product as white powder (6 mg, 11% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.69 – 7.65 (m, 1H), 7.64 – 7.59 (m, 1H), 7.38 – 7.27 (m, 9H), 7.16 (br d, J = 7.4 Hz, 2H), 6.42 – 6.35 (m, 2H), 5.87 – 5.67 (m, 1H), 4.49 – 4.27 (m, 2H). LCMS EI-MS m / z: = 429.2[M+H]+. Example 40 Synthesis of 2-(4-(dibenzylcarbamoyl)-2'-formyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1037): 2-(4-(dibenzylcarbamoyl)-2'-formyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1037) was synthesized from Int- 3a and dibenzylamine in Step 7 and then 4-formylphenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (5 mg, 5% yield).1H NMR (400 MHz, METHANOL–d4) δ = 9.92 (d, J = 6.6 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.70 (t, J = 7.5 Hz, 2H), 7.57 – 7.44 (m, 5H), 7.42 – 7.27 (m, 12H), 7.18 (br d, J = 7.3 Hz, 3H), 4.42 (br s, 2H), 3.78 (br s, 2H). LCMS EI-MS m / z: = 464.1[M+H]+. Example 41 Synthesis of 2-(4-(methylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1038): 2-(4-(methylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1038) was synthesized from Int-3a and methylamine in Step 7 and then 2-trifluoromethyl phenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (6 mg, 9% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 8.08 (d, J=8.0 Hz, 1H) 7.80 (br d, J=7.9 Hz, 1H) 7.67 (br t, J=7.5 Hz, 1H) 7.58 (br t, J=7.6 Hz, 1H) 7.25 - 7.46 (m, 3H) 4.08 (s, 2H) 3.67 (s, 3H). LCMS EI-MS m / z: = 339.0[M+H]+. Example 42 Synthesis of 2-(4-((3,4-dichlorobenzyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1039): 2-(4-(methylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1039) was synthesized from Int-3a and 3,4-dichlorobenzylamine in Step 7 and then 2-trifluoromethyl phenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (20 mg, 20% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 7.79 (d, J=7.7 Hz, 1H) 7.70 - 7.47 (m, 5H) 7.41 - 7.28 (m, 4H) 4.54 (s, 2H) 3.90 (s, 2H). LCMS EI-MS m / z: = 482.0[M+H]+. Example 43 Synthesis of 2-(5-acrylamido-2-(dimethylcarbamoyl)phenyl)acetic acid (Compound 1040): 2-(5-acrylamido-2-(dimethylcarbamoyl)phenyl)acetic acid (Compound 1040) was synthesized from 4-bromo-2- (2-ethoxy-2-oxoethyl)benzoic acid and dimethylamine following the procedure described in Steps 7-9 for the synthesis of compound 1034 to afford the title product as white powder (75 mg, 25% yield).1H NMR (400 MHz, METHANOL-d4)δ ppm 7.71 (d, J=8.0 Hz, 1H), 7.63 (s, 1H), 7.24 (d, J=8.0 Hz, 1H), 6.46 – 6.35 (m, 2H), 5.78 (dd, J=8.8, 2.4 Hz, 1H), 3.66 (s, 1H), 3.09 (s, 3H), 2.92 (s, 3H). LCMS EI-MS m / z: = 277.1[M+H]+. Example 44 Synthesis of 2-(4-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1041): 2-(4-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1041) was synthesized from Int-3a and dimethylamine in Step 7 and then 2-trifluoromethyl phenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (50 mg, 33% yield).1H NMR (400 MHz, METHANOL-d4) δ ppm 7.79 (d, J=8.0 Hz, 1H), 7.66 (t, J=6.9 Hz, 1H), 7.62 – 7.52 (m, 1H), 7.45 – 7.25 (m, 4H), 3.74 (s, 2H), 3.12 (s, 3H), 2.95 (s, 3H). LCMS EI-MS m / z: = 352.1[M+H]+. Example 45 Synthesis of 2-(4-((cyclopropylmethyl)(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1042): 2-(4-((cyclopropylmethyl)(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1042) was synthesized from Int-3a and 1-cyclopropyl-N-methylmethanamine in Step 7 and then 2-trifluoromethyl phenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (4 mg, 5% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.79 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.57 (t, J = 7.5 Hz, 1H), 7.44 – 7.29 (m, 4H), 3.74 (br s, 2H), 3.47 (br d, J = 7.3 Hz, 1H), 3.25 – 2.95 (m, 4H), 1.25 – 0.92 (m, 1H), 0.60 (br d, J = 7.5 Hz, 2H), 0.37 (d, J = 5.0 Hz, 1H), 0.17 – 0.02 (m, 1H). LCMS EI- MS m / z: = 392.1[M+H]+. Example 46 Synthesis of 2-(2'-acryloyl-4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1043) Synthesis of tert-butyl 2-(5-bromo-2-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)phenyl)acetate (Int-4b): 4-bromo-2-(tert-butoxycarbonylmethyl)benzoic acid (400 mg, 1.3 mmol), N-methyl{[3-fluoro-4- (trifluoromethyl)phenyl]methyl}amine (290 mg, 1.4 mmol, 1.1 eq.) and HATU (630 mg, 1.6 mmol, 1.2 eq.) were taken in DMF (2 ml) under nitrogen. Triethylamine (0.5 ml, 3.2 mmol, 2.5 eq.) was added to it and the solution was stirred for the next 12 hrs at room temperature. The solution was diluted with ethyl acetate and then washed with 1 N HCl solution. The organic layer was filtered through magnesium sulfate and the filtrate was concentrated. The residue was purified on Combiflash using hexanes / ethyl acetate to afford the title compound (510 mg, 80% yield). LCMS EI- MS m / z: = 504.1, 506.1[M+H]+. Synthesis of tert-butyl 2-(4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-2'-formyl-[1,1'-biphenyl]-3- yl)acetate: tert-butyl 2-(4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-2'-formyl-[1,1'-biphenyl]-3-yl)acetate (Int-4c) was synthesized from Int-4b (366 mg, 0.73 mmol) and 2-formylphenylboronic acid (110 mg, 0.73 mmol, 1.0 eq.) following the procedure described for the synthesis of compound 1037 to afford the title compound (385 mg, 100% yield). LCMS EI-MS m / z: = 530.1[M+H]+. Synthesis of tert-butyl 2-(4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-2'-(1-hydroxyallyl)-[1,1'-biphenyl]- 3-yl)acetate (Int-4d): tert-butyl [4-({[3-fluoro-4-(trifluoromethyl)phenyl]methyl}carbamoyl)-2'-formyl-3- biphenylyl]acetate (127 mg, 0.25 mmol) was taken in THF (1 ml) in an ice-bath under nitrogen. A solution of vinyl magnesium bromide (0.42 ml, 0.7 M in THF, 1.2 eq.) was added to it and the solution was stirred for 2 hrs. The solution was quenched by adding saturated ammonium chloride solution and then extracted into ethyl acetate. The organic layer was dried over magnesium sulfate and the filtrate was concentrated to afford the title compound (135 mg, 100% yield). LCMS EI-MS m / z: = 544.2[M+H]+. Synthesis of tert-butyl 2-(2'-acryloyl-4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3- yl)acetate: tert-butyl [4-({[3-fluoro-4-(trifluoromethyl)phenyl]methyl}-N-methylcarbamoyl)-2'-(1-hydroxy-2-propenyl)-3- biphenylyl]acetate (135 mg, 0.24 mmol) was taken in dichloromethane (1 ml) under nitrogen and cooled in an ice- bath. Dess-Martin reagent (133 mg, 0.3 mmol, 1.3 eq.) was added to it and the solution was stirred at room temperature for the next 18 hrs. The solution was diluted with dichloromethane and then washed with sodium thiosulfate solution. The organic layer was dried over magnesium sulfate and the filtrate was concentrated. The residue was purified on Combiflash using dichloromethane / methanol gradient to afford the title compound (135 mg, 100% yield). LCMS EI-MS m / z: = 556.2[M+H]+. Synthesis of 2-(2'-acryloyl-4-((3-fluoro-4-(trifluoromethyl)benzyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1043): tert-butyl [2'-acryloyl-4-({[3-fluoro-4-(trifluoromethyl)phenyl]methyl}-N-methylcarbamoyl)-3-biphenylyl]acetate (135 mg, 0.24 mmol) was taken in dichloromethane (2 ml) and trifluoracetic acid (0.5 ml) was added to it. The solution was concentrated and then taken up in methanol / THF. The precipitated solids were removed by filtration and the filtrate was purified by reverse phase preparative HPLC using water / acetonitrile gradient with 0.1% formic acid to afford the title compound (15 mg, 12% yield) as a white powder.1H NMR (400 MHz, METHANOL-d4) δ ppm 7.70 (br t, J=7.57 Hz, 1H), 7.61 (br d, J=7.1 Hz, 1H), 7.57 - 7.45 (m, 3H), 7.44 - 7.19 (m, 6H), 6.36 - 6.22 (m, 1H), 5.93 (br d, J=17.5 Hz, 1H), 5.71 (d, J=10.6 Hz, 1H), 3.76 (br s, 2H), 3.07 (s, 3H) 2.96 - 2.88 (m, 2H). LCMS EI-MS m / z: = 500.2[M+H]+. Example 47 Synthesis of 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1044): 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1044) was synthesized from Int-4a and 1-cyclohexyl-N-methylmethanamine in Step 12, 2-trifluoromethyl phenylboronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound1043 to afford the title product as white powder (21 mg, 33% yield). LCMS EI-MS m / z: = 434.2[M+H]+. Example 48 Synthesis of 2-(2'-carbamoyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1045): 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1045) was synthesized from Int-4a and dimethylamine in Step 12, (2-carbamoylphenyl)boronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (20 mg, 36% yield). LCMS EI-MS m / z: = 327.2[M+H]+. Example 49 Synthesis of 2-(4-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1046): 2-(4-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1046) was synthesized from 4-bromo-2-(1-ethoxy-1-oxopropan-2-yl)benzoic acid and dimethylamine in Step 7 and then 2- trifluoromethyl phenylboronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (5 mg, 4% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.79 (d, J = 7.9 Hz, 1H), 7.67 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.6 Hz, 2H), 7.30 (s, 2H), 3.80 (br d, J = 7.1 Hz, 1H), 3.16 (s, 3H), 2.95 (s, 3H), 1.46 (d, J = 7.1 Hz, 3H). LCMS EI-MS m / z: = 366.0[M+H]+. Example 50 Synthesis of 2-(2-(dimethylcarbamoyl)-5-(1-methyl-1H-pyrazol-3-yl)phenyl)acetic acid (Compound 1047): 2-(2-(dimethylcarbamoyl)-5-(1-methyl-1H-pyrazol-3-yl)phenyl)acetic acid (Compound 1047) was synthesized from Int-4a and 1-cyclohexyl-N-methylmdimethylamine ethanamine in Step 12, (1-methyl-1H-pyrazol-3-yl)boronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (15 mg, 30% yield). LCMS EI-MS m / z: = 288.2[M+H]+. Example 51 Synthesis of 2-(4-(dimethylcarbamoyl)-2'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1048): 2-(4-(dimethylcarbamoyl)-2'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1048) was synthesized from Int- 4a and dimethylamine in Step 12, 2-tolylboronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (30 mg, 51% yield). LCMS EI-MS m / z: = 288.2[M+H]+. Example 52 Synthesis of 2-(3-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1049): 2-(3-(dimethylcarbamoyl)-2'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1049) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12, 2-trifluoromethyl phenylboronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (5 mg, 4% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.79 (d, J = 7.9 Hz, 1H), 7.70 – 7.63 (m, 1H), 7.58 (br d, J = 7.8 Hz, 1H), 7.47 – 7.33 (m, 4H), 7.20 (s, 1H), 4.09 (s, 1H), 3.74 (br s, 2H), 3.09 (s, 3H), 2.93 (s, 3H). LCMS EI-MS m / z: = 352.2[M+H]+. Example 53 Synthesis of 2-(2'-acryloyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1050): 2-(2'-acryloyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1050) was synthesized from Int-4a and dimethylamine in Step 12, following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (15 mg, 28% yield). LCMS EI-MS m / z: = 338.1[M+H]+. Example 54 Synthesis of 2-(2'-carbamoyl-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1051): 22-(2'-carbamoyl-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1051) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12, (2-carbamoylphenyl)boronic acid in Step 13 and then Step 15 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (15 mg, 24% yield). LCMS EI-MS m / z: = 327.1[M+H]+. Example 55 Synthesis of 2-(2'-carbamoyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1052): 2-(2'-carbamoyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1052) was synthesized from 4-bromo-2-(1-ethoxy-1-oxopropan-2-yl)benzoic acid and dimethylamine in Step 7 and then (2- carbamoylphenyl)boronic acid in Step 10 following the procedure described for the synthesis of compound 1035 to afford the title product as white powder (6 mg, 4% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.60 – 7.50 (m, 3H), 7.48 – 7.41 (m, 3H), 7.29 (s, 1H), 3.15 (s, 3H), 2.94 (s, 3H), 1.51 (d, J = 7.1 Hz, 3H). LCMS EI-MS m / z: = 341.1[M+H]+. Example 56 Synthesis of 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1053): 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1053) was synthesized from Int-4a and 1-cyclohexyl-N-methylmethanamine in Step 12, following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (8 mg, 9% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.73 – 7.57 (m, 1H), 7.57 – 7.47 (m, 3H), 7.37 – 7.23 (m, 3H), 6.33 – 6.21 (m, 1H), 5.99 – 5.85 (m, 1H), 5.75 – 5.62 (m, 1H), 3.69 (br s, 1H), 3.60 (s, 1H), 3.47 – 3.32 (m, 2H), 3.12 – 3.03 (m, 2H), 2.89 (s, 2H), 1.87 – 1.74 (m, 4H), 1.74 – 1.56 (m, 3H), 1.38 – 1.17 (m, 3H), 1.17 – 0.99 (m, 2H), 0.71 (q, J = 11.5 Hz, 1H). LCMS EI-MS m / z: = 420.1[M+H]+. Example 57 Synthesis of 2-(2'-acryloyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1054): 2-(2'-acryloyl-4-(dimethylcarbamoyl)-[1,1'-biphenyl]-3-yl)propanoic acid (Compound 1054) was synthesized from 4-bromo-2-(1-ethoxy-1-oxopropan-2-yl)benzoic acid and dimethylamine in Step 12, following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (18 mg, 13% yield). LCMS EI-MS m / z: = 352.1[M+H]+. Example 58 Synthesis of 2-(2'-carbamoyl-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1055): 22-(2'-carbamoyl-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1055) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (10 mg, 9% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.56 – 7.39 (m, 6H), 7.33 (s, 1H), 3.72 (br s, 2H), 3.10 (s, 3H), 2.97 (s, 3H). LCMS EI-MS m / z: = 338.1[M+H]+. Example 59 Synthesis of 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1056): 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1056) was synthesized from Int-4a and 1-cyclohexyl-N-methylmethanamine in Step 12, and (2-formyl-5-methylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (12 mg, 11% yield). LCMS EI-MS m / z: = 434.1[M+H]+. Example 60 Synthesis of 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-2'-(1-hydroxyallyl)-5'-methyl-[1,1'-biphenyl]-3- yl)acetic acid (Compound 1057): 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-2'-(1-hydroxyallyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1057) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1056 to afford the title product as white powder (12 mg, 11% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.61 – 7.51 (m, 1H), 7.40 – 7.16 (m, 6H), 7.13 (br s, 1H), 6.54 (s, 1H), 6.27 (br dd, J = 6.0, 15.6 Hz, 1H), 5.13 – 5.00 (m, 1H), 4.99 – 4.92 (m, 2H), 4.13 (d, J = 5.6 Hz, 1H), 3.82 – 3.58 (m, 3H), 3.53 – 3.35 (m, 2H), 3.21 – 3.04 (m, 2H), 2.98 – 2.85 (m, 3H), 2.39 (br d, J = 7.8 Hz, 4H), 1.96 – 1.77 (m, 5H), 1.77 – 1.56 (m, 4H), 1.41 – 1.19 (m, 4H), 1.19 – 1.01 (m, 2H). LCMS EI-MS m / z: = 418.1[M-H2O+H]+. Example 61 Synthesis of 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-fluoro-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1058): 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-fluoro-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1058) was synthesized from Int-4a and 1-cyclohexyl-N-methylmethanamine in Step 12, and (2-formyl-5- fluorophenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (16 mg, 15% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.47 (d, J = 7.4 Hz, 1H), 7.39 – 7.24 (m, 5H), 6.33 – 6.23 (m, 1H), 5.98 – 5.90 (m, 1H), 5.70 – 5.62 (m, 1H), 3.72 (br s, 1H), 3.69 – 3.57 (m, 1H), 3.49 – 3.35 (m, 2H), 3.15 – 3.03 (m, 2H), 2.97 – 2.88 (m, 2H), 2.50 – 2.43 (m, 3H), 1.89 – 1.77 (m, 4H), 1.77 – 1.56 (m, 4H), 1.40 – 1.20 (m, 3H), 1.18 – 1.01 (m, 2H), 0.73 (br d, J = 11.8 Hz, 1H). LCMS EI-MS m / z: = 438.1[M+H]+. Example 62 Synthesis of 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1059): 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1059) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1058 to afford the title product as white powder (110 mg, 90% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.73 (br dd, J = 5.7, 8.6 Hz, 1H), 7.68 – 7.51 (m, 2H), 7.43 – 7.29 (m, 9H), 7.24 – 6.98 (m, 7H), 6.75 (br d, J = 15.9 Hz, 1H), 6.34 – 6.16 (m, 1H), 6.03 – 5.85 (m, 2H), 5.26 – 5.14 (m, 2H), 5.13 – 4.99 (m, 4H), 4.99 – 4.93 (m, 3H), 4.14 (d, J = 5.5 Hz, 1H), 3.77 (br s, 4H), 3.68 (br d, J = 4.5 Hz, 2H), 3.52 – 3.35 (m, 5H), 3.12 (s, 5H), 2.98 – 2.87 (m, 6H), 1.92 – 1.78 (m, 11H), 1.78 – 1.57 (m, 9H), 1.41 – 1.19 (m, 9H), 1.19 – 1.02 (m, 5H), 0.77 (br d, J = 12.3 Hz, 2H). LCMS EI-MS m / z: = 421.1[M-H2O+H]+. Example 63 Synthesis of 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-4'-fluoro-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1060): 2-(2'-acryloyl-4-((cyclohexylmethyl)(methyl)carbamoyl)-5'-fluoro-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1060) was synthesized from Int-4a and 1-cyclohexyl-N-methylmethanamine in Step 12, and (4-fluoro-2- formylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (12 mg, 15% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.64 – 7.46 (m, 1H), 7.43 – 7.21 (m, 6H), 6.32 – 6.21 (m, 1H), 6.02 – 5.90 (m, 1H), 5.79 – 5.68 (m, 1H), 3.68 – 3.56 (m, 1H), 3.50 – 3.35 (m, 2H), 3.15 – 3.02 (m, 2H), 2.99 – 2.81 (m, 3H), 1.76 – 1.56 (m, 4H), 1.40 – 1.19 (m, 3H), 1.19 – 1.00 (m, 2H), 0.73 (br d, J = 11.5 Hz, 1H). LCMS EI-MS m / z: = 438.1[M+H]+. Example 64 Synthesis of 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-4'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1061): 2-(4-((cyclohexylmethyl)(methyl)carbamoyl)-4'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1061) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1060 to afford the title product as white powder (78 mg, 95% yield). LCMS EI-MS m / z: = 421.1[M-H2O+H]+. Example 65 Synthesis of 2-(2'-acryloyl-4-(dimethylcarbamoyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1062): 2-(2'-acryloyl-4-(dimethylcarbamoyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1062) was synthesized from Int-4a and dimethylamine in Step 12, and (2-formyl-5-methylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (21 mg, 25% yield). LCMS EI-MS m / z: = 352.1[M+H]+. Example 66 Synthesis of 2-(4-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1063): 2-(4-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-5'-methyl-[1,1'-biphenyl]-3-yl)acetic acid (Compound 1063) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1062 to afford the title product as white powder (78 mg, 95% yield). LCMS EI-MS m / z: = 334.1[M-H2O+H]+. Example 67 Synthesis of 2-(2'-acryloyl-3-(dimethylcarbamoyl)-4'-fluoro-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1064): 2-(2'-acryloyl-3-(dimethylcarbamoyl)-4'-fluoro-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1064) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12 and (4-fluoro-2- formylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (10 mg, 11% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.43 – 7.15 (m, 6H), 7.02 (d, J = 1.9 Hz, 1H), 6.22 (dd, J = 10.5, 17.5 Hz, 1H), 5.87 (dd, J = 1.0, 17.5 Hz, 1H), 5.72 (dd, J = 1.0, 10.6 Hz, 1H), 3.60 (s, 2H), 3.04 – 2.89 (m, 3H), 2.84 – 2.75 (m, 3H). LCMS EI-MS m / z: = 356.1[M+H]+. Example 68 Synthesis of 2-(3-(dimethylcarbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1067): 2-(3-(dimethylcarbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1067) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1064 to afford the title product as white powder (140 mg, 97% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.48 (d, J = 7.9 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.33 – 7.20 (m, 3H), 7.13 – 7.06 (m, 1H), 5.95 (ddd, J = 5.3, 10.5, 17.1 Hz, 1H), 5.25 – 5.15 (m, 1H), 5.13 – 4.93 (m, 3H), 3.75 (s, 2H), 3.12 (s, 3H), 2.96 (s, 3H). LCMS EI-MS m / z: = 339.1[M-H2O+H]+. Example 69 Synthesis of 2-(2'-acryloyl-3-(dimethylcarbamoyl)-5'-fluoro-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1066): 2-(2'-acryloyl-3-(dimethylcarbamoyl)-5'-fluoro-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1066) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12 and (5-fluoro-2- formylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (9 mg, 10% yield). LCMS EI-MS m / z: = 356.1[M+H]+. Example 70 Synthesis of 2-(3-(dimethylcarbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1065): 2-(3-(dimethylcarbamoyl)-5'-fluoro-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1065) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1066 to afford the title product as white powder (78 mg, 95% yield). LCMS EI-MS m / z: = 339.1[M-H2O+H]+. Example 71 Synthesis of 2-(2'-acryloyl-5'-chloro-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1069): 22-(2'-acryloyl-5'-chloro-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1069) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12 and (5-chloro-2- formylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (8 mg, 8% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.57 – 7.51 (m, 3H), 7.47 (d, J = 7.8 Hz, 1H), 7.38 (dd, J = 1.8, 7.9 Hz, 1H), 7.16 (d, J = 1.8 Hz, 1H), 6.40 – 6.31 (m, 1H), 5.99 (d, J = 17.4 Hz, 1H), 5.83 (d, J = 10.6 Hz, 1H), 3.73 (br s, 2H), 3.12 – 3.09 (m, 3H), 2.97 – 2.86 (m, 3H). LCMS EI-MS m / z: = 372.1[M+H]+. Example 72 Synthesis of 2-(5'-chloro-3-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1068): 2-(5'-chloro-3-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1068) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1068 to afford the title product as white powder (78 mg, 95% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.58 (d, J = 8.5 Hz, 1H), 7.47 – 7.22 (m, 5H), 7.21 – 7.07 (m, 1H), 5.85 (ddd, J = 5.3, 10.5, 17.1 Hz, 1H), 5.09 – 4.97 (m, 2H), 4.96 – 4.88 (m, 1H), 3.64 (br s, 2H), 3.04 – 2.94 (m, 3H), 2.88 – 2.75 (m, 3H). LCMS EI-MS m / z: = 355.1[M-H2O+H]+. Example 73 Synthesis of 2-(2'-acryloyl-4'-chloro-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1070): 22-(2'-acryloyl-4'-chloro-3-(dimethylcarbamoyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1070) was synthesized from 5-bromo-2-(2-(tert-butoxy)-2-oxoethyl)benzoic acid and dimethylamine in Step 12 and (4-chloro-2- formylphenyl)boronic acid in Step 13 following the procedure described for the synthesis of compound 1043 to afford the title product as white powder (9 mg, 11% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.56 – 7.46 (m, 1H), 7.42 – 7.29 (m, 4H), 7.29 – 7.19 (m, 1H), 7.03 (d, J = 1.9 Hz, 1H), 6.22 (dd, J = 10.5,17.5 Hz, 1H), 5.87 (d, J = 17.4 Hz, 1H), 5.73 (d, J = 10.6 Hz, 1H), 3.60 (br s, 2H), 3.04 – 2.90 (m, 3H), 2.85 – 2.73 (m, 3H). LCMS EI-MS m / z: = 372.1[M+H]+. Example 74 Synthesis of 2-(4'-chloro-3-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1071): 2-(4'-chloro-3-(dimethylcarbamoyl)-2'-(1-hydroxyallyl)-[1,1'-biphenyl]-4-yl)acetic acid (Compound 1071) was synthesized from Steps 12, 13, 14 and 16 following the procedure described for the synthesis of compound 1070 to afford the title product as white powder (90 mg, 92% yield).1H NMR (400 MHz, METHANOL–d4) δ = 7.46 (d, J = 2.3 Hz, 1H), 7.36 (d, J = 7.5 Hz, 1H), 7.31 – 7.20 (m, 2H), 7.16 – 7.09 (m, 2H), 5.83 (ddd, J= 5.3, 10.5, 17.0 Hz, 1H), 5.07 (d, J = 5.3 Hz, 1H), 5.02 – 4.85 (m, 2H), 3.64 (s, 2H), 3.00 (s, 3H), 2.84 (s, 3H). LCMS EI-MS m / z: = 355.1[M- H2O+H]+. INCORPORATION BY REFERENCE All patents and publications referenced herein are hereby incorporated by reference in their entireties. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. As used herein, all headings are simply for organization and are not intended to limit the disclosure in any manner. The content of any individual section may be equally applicable to all sections. EQUIVALENTS While the disclosure has been disclosed in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure as come within known or customary practice within the art to which the disclosure pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments disclosed specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

Claims

CLAIMS What is claimed is:

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:formula (I) wherein in formula (I): A is selected from, , , , ,L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1is an integer from 0 to 5; t is 1 or 2;with the proviso that the compound of formula (I) is not a compound of any one of formulas 1001, 1003, 1004, and 1006-1009:

2. The compound of claim 1, wherein R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, optionally substituted with halo, unsubstituted or substituted alkyl, and / or unsubstituted or substituted heterocyclyl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, halo, - C(O)Ra, -C(O)N(Ra)2, -N(Ra)2, -N(Ra)C(O)Ra, and -S(O)tRa.

3. The compound of claim 1 or 2, wherein L is a bond or comprises one or more linking groups selected from unsubstituted or substituted -C1-10alkyl-, -O-C1-10alkyl-, -C1-10alkenyl-, -O-C1-10alkenyl-, -C1-10cycloalkenyl-, -O-C1-10cycloalkenyl-, -C1-10 alkynyl-, -O-C1-10 alkynyl-, -C1-10 aryl-, -O-C1-10-, -aryl-,-cycloalkyl-, -heterocyclyl-, -O-, -S-, -S-S-, - S(O)w-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -OC(O)O-, -N(Rb)-, -C(O)N(Rb)-, -N(Rb)C(O)-, -OC(O)N(Rb)-, - N(Rb)C(O)O-, -SC(O)N(Rb)-, -N(Rb)C(O)S-, -N(Rb)C(O)N(Rb)-, -N(Rb)C(NRb)N(Rb)-, -N(Rb)S(O)w-, -S(O)wN(Rb)-, - S(O)wO-, -OS(O)w-, -OS(O)wO-, -O(O)P(ORb)O-, (O)P(O-)3, -O(S)P(ORb)O-, and (S)P(O-)3, wherein w is 1 or 2, and Rbis independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, optionally L is a bond and / or - ;4. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (10):formula (10) wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl;n2is an integer from 0 to 5; and t is 1 or 2.

5. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (20) or (21):formula (20) formula (21) wherein in formula (20) and (21): n3 is an integer from 0 to 5.

6. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (30) or (31):formula (30) formula (31) wherein in formula (30) and (31): p is an integer from 0 to 5.

7. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (32):wherein in formula (32): q is an integer from 1 to 3.

8. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (40):wherein in formula (40): n4 is an integer from 0 to 5.

9. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (50):formula (50) wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5is an integer from 0 to 5; and t is 1 or 2.

10. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (60):formula (60) wherein in formula (60): n6 is an integer from 0 to 5.

11. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (70):formula (70) wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl.

12. The compound of claim 11, wherein the compound of formula (70) is a compound of formula (700) or (701):formula (700) formula (701).

13. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (80) or formula (81):wherein in formula (80): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5;wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted orsubstituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl.

14. The compound of claim 13, wherein the compound of formula (80) is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803):Formula (802) formula (803).

15. The compound of any one of claims 11-14, wherein R5band / or R5cis each independently selected from unsubstituted or substituted alkynyl, optionally substituted alkynyl, substituted aryl, substituted heteroaryl, halo, optionally Br, -N(Ra)2, optionally -NH2, and -N(Ra)C(O)Ra, optionally,, , n ,16. The compound of any one of claims 11-15, wherein R11aand R11bare each unsubstituted alkyl, or R11aand R11bare each independently, or R11ais selected from H and unsubstituted alkyl and R11bis, or R11ais H and R11bis unsubstituted alkyl, wherein Y is selected from unsubstituted or substituted alkyl, optionally unsubstituted or substituted C1-C5alkyl, unsubstituted or substituted aryl, optionally unsubstituted or substituted phenyl, unsubstituted or substituted cycloalkyl, optionally unsubstituted or substituted C3-C7cycloalkyl, and unsubstituted or substituted alkoxy, optionally unsubstituted or substituted C1-C5alkoxy, and n7is an integer from 1 to 3, optionally n7i ,aa ,17. The compound of claim 16, wherein R11ais selected from H and -CH3 and R11bis selected from, d, ,3.

18. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (82):formula (82) wherein in formula (82): R11a, R11b, R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl.

19. The compound of claim 18, wherein the compound of formula (82) is a compound of formula (804) or (805):

20. The compound of any one of claims 1-3, wherein the compound of formula (I) is a compound of formula (90):formula (90) wherein in formula (90): n is an integer from 1 to 5.

21. The compound of claim 20, wherein the compound of formula (90) is a compound of formula (900). formula (901), or formula (902):formula (900) formula (901) formula (902).

22. The compound of claim 20 or 21, wherein R11ais H or substituted alkyl, optionally, optionally23. The compound of any one of claims 20-22, wherein R10is -C(O)Ra, optionally wherein Rais selected from unsubstituted alkenyl, substituted alkyl, substituted aryl, and substituted heterocyclyl, or R10is -S(O)tRa, optionally wherein t is 2 and Rais substituted aryl, optionally wherein R10is selected from:

24. The compound of any one of claims 1-3 or 11-23, wherein the compound of formula (I) is a compound of any one of formula 1002, 1005, 1010-1098, or a pharmaceutically acceptable salt thereof:

25. The compound of any one of claims 1-3 or 11-24, wherein the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof:

26. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient:formula (I) wherein in formula (I):,L is a linking group; R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, R5c, R5d, R5e, R6a, R6b, R6c, R6d, R6e, R7a, R7b, R7c, R7d, R8, R9, R10, R11a, R11b, and R11care each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; R12is H or unsubstituted alkyl; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n1 is an integer from 0 to 5; and t is 1 or 2.

27. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (10):formula (10) wherein in formula (10): R9a, R9b, R9c, R9d, and R9eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n2is an integer from 0 to 5; and t is 1 or 2.

28. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (20) or (21):formula (20) formula (21) wherein in formula (20) and (21): n3 is an integer from 0 to 5.

29. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (30) or (31):formula (30) formula (31) wherein in formula (30) and (31): p is an integer from 0 to 5.

30. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (32):formula (32) wherein in formula (32): q is an integer from 1 to 3.

31. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (40):formula (40) wherein in formula (40): n4is an integer from 0 to 5.

32. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (50):formula (50) wherein in formula (50): R10a, R10b, R10c, R10d, and R10eare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; n5is an integer from 0 to 5; and t is 1 or 2.

33. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (60):formula (60) wherein in formula (60): n6is an integer from 0 to 5.

34. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (70):formula (70) wherein in formula (70): R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl, optionally wherein the compound of formula (70) is a compound of formula (700) or (701):formula (700) formula (701).

35. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (80) or formula (81):formula (80) wherein in formula (80):R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl; and n8is an integer from 1 to 5;wherein in formula (81): Alk is unsubstituted or substituted alkyl; R11aand R11bare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)SRa, - OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, - S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; and Rais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substitutedheteroarylalkyl, optionally wherein the compound of formula (80) is a compound of formula (800) or formula (801), or the compound of formula (81) is a compound of formula (802) or formula (803):Formula (802) formula (803).

36. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (82):formula (82) wherein in formula (82): R11a, R11b, R11c, and R11dare each independently selected from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted heteroalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heteroarylalkyl, hydroxy, halo, cyano, trifluoromethyl, trifluoromethoxy, nitro, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -SC(O)-Ra, -N(Ra)2, - C(O)Ra, -C(O)ORa, -C(O)SRa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, - N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tRa, -S(O)tRa, -S(O)tORa, -S(O)tN(Ra)2, and PO3(Ra)2; andRais independently selected at each occurrence from hydrogen, unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heterocyclyl, unsubstituted or substituted heterocycloalkyl, unsubstituted or substituted heteroaryl, and unsubstituted or substituted heteroarylalkyl, optionally wherein the compound of formula (82) is a compound of formula (804) or (805):

37. The pharmaceutical composition of claim 26, wherein the compound of formula (I) is a compound of formula (90):formula (90) wherein in formula (90): n is an integer from 1 to 5, optionally wherein the compound of formula (90) is a compound of formula (900), formula (901), or formula (902):

38. The pharmaceutical composition of any one of claims 26 or 34-37, wherein the compound of formula (I) is a compound of any one of formula 1001-1098, or a pharmaceutically acceptable salt thereof:

39. The pharmaceutical composition of any one of claims 26 or 34-38, wherein the compound of formula (I) is a compound of any one of formula 1010, 1011, 1020-1030, 1034, 1036, 1037, 1040, 1043, 1050, 1053-1056, 1058, 1060, 1062, 1064, 1066, 1069, 1070, 1075, 1084, or a pharmaceutically acceptable salt thereof:

40. A method for treating a cancer, an infectious disease, an inflammatory disease in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any one of claims 26-39,optionally wherein the cancer is resistant to an anti-checkpoint agent, optionally wherein the anti-checkpoint agent is an antibody, optionally selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and anti-CTLA antibody.

41. The method of claim 40, wherein the cancer is selected from a basal cell carcinoma, biliary tract cancer; bladder cancer; bone cancer; brain and central nervous system cancer; breast cancer; cancer of the peritoneum; cervical cancer; choriocarcinoma; colon and rectum cancer; connective tissue cancer; cancer of the digestive system; endometrial cancer; esophageal cancer; eye cancer; cancer of the head and neck; gastric cancer (including gastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma; intra-epithelial neoplasm; kidney or renal cancer; larynx cancer; leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavity cancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreatic cancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectal cancer; cancer of the respiratory system; salivary gland carcinoma; sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicular cancer; thyroid cancer; uterine or endometrial cancer; cancer of the urinary system; vulval cancer; lymphoma including Hodgkin’s and non-Hodgkin’s lymphoma, as well as B-cell lymphoma (including low grade / follicular non-Hodgkin’s lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade / follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom’s Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; as well as other carcinomas and sarcomas; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema (such as that associated with brain tumors), and Meigs’ syndrome.

42. The method of claim 40 or 41, wherein the cancer is a hematologic cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), acute leukemias, acute lymphoid leukemia (ALL), B-cell acute lymphoid leukemia (B-ALL), T-cell acute lymphoid leukemia (T-ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt’s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndrome, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, and pre-leukemia, or a combination thereof.

43. The method of claim 40, wherein the infectious disease is a viral infection, optionally wherein the viral infection is caused by a virus selected from papilloma virus, herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis virus, Zika virus, Yellow Fever Virus, West Nile virus, Dengue virus, Japanese Encephalitis Virus, St. Louis Encephalitis Virus, Hepatitis C Virus, poliovirus, rhinovirus, enterovirus, coxsackievirus, influenza virus, lentivirus,respiratory syncytial virus, a human parainfluenza virus, rubulavirus (e.g., mumps virus), measles virus, human metapneumovirus, hantavirus, rotavirus, norovirus, and SARS virus (e.g., SARS-CoV-2).

44. The method of claim 40, wherein the inflammatory disease is an autoimmune disease or condition, selected from multiple sclerosis, diabetes mellitus, lupus, celiac disease, Crohn’s disease, ulcerative colitis, Guillain-Barre syndrome, scleroderms, Goodpasture’s syndrome, Wegener’s granulomatosis, autoimmune epilepsy, Rasmussen’s encephalitis, Primary biliary sclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addisohn’s disease, Hashimoto’s thyroiditis, Fibromyalgia, Menier’s syndrome; transplantation rejection (e.g., prevention of allograft rejection) pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren’s syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter’s syndrome, Grave’s disease, and other autoimmune disease.

45. A method for treating an anti-checkpoint agent-resistant cancer in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition of any one of claims 26-39.

46. A method of determining a cancer treatment for a patient, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any one of claims 26-39 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody.

47. A method for selecting a patient for a cancer treatment, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) selecting the cancer therapy comprising the pharmaceutical composition of any one of claims 26-39 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from thesubject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally selecting a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody.

48. A method of treating cancer, the method comprising: (a) obtaining a biological sample from a subject; (b) evaluating the biological sample for the expression of Trim7; and (c) administering the cancer therapy comprising the pharmaceutical composition of any one of claims 26-39 if the Trim7 is upregulated compared to a compared to a healthy tissue, a prior biological sample obtained from the subject, or another biological sample from patient that is known to be sensitive to an anti-checkpoint agent; and (d) optionally administering a second cancer therapy comprising an anti-checkpoint agent, wherein the anti- checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA agent, optionally wherein the anti-checkpoint agent is selected from an anti-PD-1, anti-PD-L1, anti-PD-L2, and / or anti-CTLA antibody.

49. The method of any one of claims 46-48, wherein the biological sample is a fresh tissue sample, frozen tumor tissue specimen, cultured cells, circulating tumor cells, or a formalin-fixed paraffin-embedded tumor tissue specimen.

50. The method of any one of claims 46-48, wherein the biological sample is a biopsy sample, optionally wherein the biopsy sample is selected from endoscopic biopsy, bone marrow biopsy, endoscopic biopsy (e.g., cystoscopy, bronchoscopy and colonoscopy), needle biopsy (e.g., fine-needle aspiration, core needle biopsy, vacuum-assisted biopsy, X-ray-assisted biopsy, computerized tomography (CT)-assisted biopsy, magnetic resonance imaging (MRI)- assisted biopsy and ultrasound-assisted biopsy), skin biopsy (e.g., shave biopsy, punch biopsy, and incisional biopsy) and surgical biopsy, optionally wherein the biological sample comprises a body fluid selected from blood, plasma, serum, lacrimal fluid, tears, bone marrow, blood, blood cells, ascites, tissue or fine needle biopsy sample, cell- containing body fluid, free floating nucleic acids, sputum, saliva, urine, cerebrospinal fluid, peritoneal fluid, pleural fluid, feces, lymph, gynecological fluid, skin swab, vaginal swab, oral swab, nasal swab, washing or lavage such as a ductal lavage or broncheoalveolar lavage, aspirate, scraping, bone marrow specimen, tissue biopsy specimen, surgical specimen, feces, other body fluids, secretions, and / or excretions, and / or cells therefrom, optionally wherein the biological sample comprises at least one tumor cell.

51. The method of any one of claims 46-50, wherein the evaluating is performed by DNA sequencing, RNA sequencing, immunohistochemical staining, western blotting, in cell western, immunofluorescent staining, ELISA, and fluorescent activating cell sorting (FACS) or a combination thereof, or the evaluating is performed by contacting the sample with an agent that specifically binds to Trim7, optionally wherein the agent that specifically binds to one or proteins comprises an antibody, antibody-like molecule or binding a fragment thereof, or the evaluating is performed by contacting the sample with an agent that specifically binds to one or more of nucleic acids of Trim7, optionally wherein the agent that specifically binds to one or more of the nucleic acids is a nucleic acid primer or probe.

Images